drTarget portfolio target-disease associations for immune system DrTarget’s AI-Powered Indication Expansion for Immune Disorders

DrTarget’s AI-Powered Insights into Immune System Disorders

DrTarget has identified 343 target proteins from PubChem screens linked to 475 immune-related diseases, leveraging Open Targets and other public data sources. By applying machine learning models and AI-driven analytics, we uncover new therapeutic targets and drug repurposing opportunities for autoimmune, inflammatory, and immunodeficiency disorders.

Our AI-powered approach enables:

✔ Identification of key targets for autoimmune and inflammatory diseases
✔ Drug repurposing opportunities for immune-modulating therapies
✔ Pathway and biomarker analysis for precision immunology

By integrating AI-driven virtual screening with multi-source validation, DrTarget accelerates the discovery of next-generation immunotherapies to enhance treatment options for immune disorders.

Target-disease associations for immune diseases.

Check best scored target-disease associations in table:

PubChemAssay	program	diseaseName	assayType	testedCompounds	activeCompounds	associationScore	numberOfEvidences
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Crohn's disease	targetBased	217959	2390	0.66633861809884	35
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	Crohn's disease	targetBased	143816	859	0.369489609878927	8
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	Crohn's disease	targetBased	363803	1383	0.332442928560379	8
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	Crohn's disease	pathwayBased	193265	3100	0.332959636528519	7
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	Crohn's disease	pathwayBased	359244	3094	0.332959636528519	7
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	Crohn's disease	targetBased	394050	3624	0.614524204063885	20
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	Crohn's disease	targetBased	67275	2509	0.297910135217532	32
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	Crohn's disease	targetBased	326888	645	0.737705438254737	75
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	Crohn's disease	targetBased	75924	1804	0.340694061111576	7
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	Crohn's disease	targetBased	325247	1021	0.379885398185413	20
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	Crohn's disease	targetBased	217959	771	0.325348050422973	14
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	Crohn's disease	targetBased	217959	569	0.325348050422973	14
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Crohn's disease	targetBased	99314	335	0.606813177486441	22
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Crohn's disease	targetBased	196176	782	0.606813177486441	22
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Crohn's disease	targetBased	99314	390	0.606813177486441	22
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Crohn's disease	targetBased	196177	811	0.606813177486441	22
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Crohn's disease	targetBased	196176	670	0.606813177486441	22
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Crohn's disease	targetBased	196177	519	0.606813177486441	22
uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)	p47phoxInhibitors	Crohn's disease	targetBased	217454	1142	0.266249542498813	6
HTS of Smad transcription factor inhibitors	SMAD3	Crohn's disease	targetBased	88033	251	0.51331093980131	8
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	Crohn's disease	targetBased	292323	1836	0.923073177649278	1414
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	Crohn's disease	pathwayBased	194666	1772	0.5018282116886	13
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	Crohn's disease	pathwayBased	194666	1722	0.5018282116886	13
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	Crohn's disease	targetBased	55710	315	0.424333797212919	22
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	atopic eczema	pathwayBased	64908	979	0.295300014382582	7
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	atopic eczema	pathwayBased	64908	278	0.295300014382582	7
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	atopic eczema	targetBased	217959	2390	0.623231800016832	67
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	atopic eczema	targetBased	324747	7988	0.410445598825414	13
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	atopic eczema	targetBased	75924	1804	0.417866746569554	23
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	atopic eczema	targetBased	316642	617	0.316542135854887	11
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	atopic eczema	targetBased	394050	3624	0.439677534307829	6
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	rheumatoid arthritis	targetBased	86095	1442	0.41826550590229	30
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	rheumatoid arthritis	targetBased	86095	1151	0.41826550590229	30
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	rheumatoid arthritis	targetBased	217959	2390	0.68876863655042	227
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	rheumatoid arthritis	targetBased	394050	3624	0.408905740315506	8
uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay	CCR6_antagonists	rheumatoid arthritis	targetBased	340696	1654	0.523283731423149	34
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	rheumatoid arthritis	targetBased	99314	335	0.316170628682077	16
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	rheumatoid arthritis	targetBased	196176	782	0.316170628682077	16
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	rheumatoid arthritis	targetBased	99314	390	0.316170628682077	16
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	rheumatoid arthritis	targetBased	196177	811	0.316170628682077	16
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	rheumatoid arthritis	targetBased	196176	670	0.316170628682077	16
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	rheumatoid arthritis	targetBased	196177	519	0.316170628682077	16
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS)	PADI4	rheumatoid arthritis	targetBased	326022	1334	0.687131196796391	53
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	rheumatoid arthritis	targetBased	292323	1836	0.344497760009479	15
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	rheumatoid arthritis	targetBased	316642	617	0.518622044684266	7
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	rheumatoid arthritis	targetBased	343468	734	0.666736202498445	133
HTS for developing T Cell Immune Modulators	ITGAL	psoriasis	targetBased	326271	221	0.647172633973302	119
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	psoriasis	targetBased	336894	489	0.519072092168666	26
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	psoriasis	targetBased	217959	2390	0.52623853206338	110
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	psoriasis	targetBased	324747	7988	0.687648482714935	222
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	psoriasis	pathwayBased	193265	3100	0.339337400587504	695
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	psoriasis	pathwayBased	359244	3094	0.339337400587504	695
qHTS of IL-2 Activators	IL2	psoriasis	targetBased	364617	238	0.321063444162615	207
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	psoriasis	targetBased	67275	2509	0.368222903581623	914
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	psoriasis	targetBased	325247	1021	0.318702620448013	12
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	psoriasis	targetBased	304060	10600	0.276155592989189	65
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	psoriasis	pathwayBased	7671	874	0.276155592989189	65
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	psoriasis	pathwayBased	305439	16717	0.276155592989189	65
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	psoriasis	targetBased	335777	499	0.546229169969465	140
HTS of Smad transcription factor inhibitors	SMAD3	psoriasis	targetBased	88033	251	0.437397772906933	14
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	psoriasis	pathwayBased	194666	1772	0.351463457960425	502
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	psoriasis	pathwayBased	194666	1722	0.351463457960425	502
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	psoriasis	targetBased	394050	3624	0.682247545111168	296
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	psoriasis	targetBased	316642	617	0.413899156141244	47
HTS for developing T Cell Immune Modulators	ITGAL	ulcerative colitis	targetBased	326271	221	0.261097385083632	9
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	ulcerative colitis	targetBased	194152	1342	0.464712841053478	21
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ulcerative colitis	targetBased	86095	1442	0.324962882417437	192
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ulcerative colitis	targetBased	86095	1151	0.324962882417437	192
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	ulcerative colitis	targetBased	217959	2390	0.760994816046525	161
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	ulcerative colitis	targetBased	363803	1383	0.299642360244183	21
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	ulcerative colitis	targetBased	57013	201	0.315719626583571	30
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	ulcerative colitis	targetBased	324747	7988	0.33787439712456	74
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	ulcerative colitis	targetBased	394050	3624	0.328488655948732	68
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	ulcerative colitis	targetBased	67275	2509	0.446337451033987	696
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ulcerative colitis	targetBased	326888	645	0.655877863539481	66
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	ulcerative colitis	targetBased	363803	458	0.518921467802981	15
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	ulcerative colitis	targetBased	325247	1021	0.257406185494847	30
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	ulcerative colitis	targetBased	217959	771	0.590697841480425	26
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	ulcerative colitis	targetBased	217959	569	0.590697841480425	26
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	ulcerative colitis	targetBased	99314	335	0.692888906416013	432
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	ulcerative colitis	targetBased	196176	782	0.692888906416013	432
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	ulcerative colitis	targetBased	99314	390	0.692888906416013	432
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	ulcerative colitis	targetBased	196177	811	0.692888906416013	432
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	ulcerative colitis	targetBased	196176	670	0.692888906416013	432
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	ulcerative colitis	targetBased	196177	519	0.692888906416013	432
qHTS assay for re-activators of p53 using a Luc reporter	TP53	ulcerative colitis	pathwayBased	321427	201	0.335150295135842	483
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ulcerative colitis	targetBased	54509	528	0.335150295135842	483
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ulcerative colitis	targetBased	54513	338	0.335150295135842	483
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ulcerative colitis	targetBased	125394	1890	0.335150295135842	483
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	ulcerative colitis	targetBased	124022	1156	0.335150295135842	483
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	ulcerative colitis	targetBased	356517	1139	0.328864540185122	323
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	ulcerative colitis	targetBased	304060	10600	0.385177046740896	41
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	ulcerative colitis	pathwayBased	7671	874	0.385177046740896	41
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	ulcerative colitis	pathwayBased	305439	16717	0.385177046740896	41
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	ulcerative colitis	targetBased	322361	619	0.30837818021927	33
HTS of Smad transcription factor inhibitors	SMAD3	ulcerative colitis	targetBased	88033	251	0.477180480331524	32
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	ulcerative colitis	targetBased	292323	1836	0.802339118184399	318
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	ulcerative colitis	pathwayBased	194666	1772	0.359123268930043	351
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	ulcerative colitis	pathwayBased	194666	1722	0.359123268930043	351
OTUD3 deubiquitinase inhibition: Primary qHTS	OTUD3	ulcerative colitis	targetBased	47480	334	0.343824520808528	39
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	ulcerative colitis	targetBased	55710	315	0.644099885304213	123
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	ulcerative colitis	pathwayBased	43989	342	0.42005545401222	150
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	celiac disease	targetBased	358434	2554	0.269403932902958	14
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	ulcerative colitis	targetBased	343468	734	0.354954988090465	61
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	ulcerative colitis	pathwayBased	193265	3100	0.494586180209997	950
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	ulcerative colitis	pathwayBased	359244	3094	0.494586180209997	950
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	colitis	targetBased	217959	2390	0.457463840244192	110
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	colitis	targetBased	326888	645	0.274984130748396	35
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colitis	targetBased	99314	335	0.305284900636795	518
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colitis	targetBased	196176	782	0.305284900636795	518
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colitis	targetBased	99314	390	0.305284900636795	518
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colitis	targetBased	196177	811	0.305284900636795	518
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colitis	targetBased	196176	670	0.305284900636795	518
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colitis	targetBased	196177	519	0.305284900636795	518
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	colitis	targetBased	304060	10600	0.29549917499103	62
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	colitis	pathwayBased	7671	874	0.29549917499103	62
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	colitis	pathwayBased	305439	16717	0.29549917499103	62
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	colitis	targetBased	292323	1836	0.346136900375504	358
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	antiphospholipid syndrome	targetBased	343468	734	0.317964370558289	6
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	inflammatory bowel disease	targetBased	396029	13426	0.276235168570378	134
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	inflammatory bowel disease	targetBased	395981	5516	0.276235168570378	134
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	inflammatory bowel disease	targetBased	194152	1342	0.442884054302183	14
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	inflammatory bowel disease	targetBased	217959	2390	0.577230617368294	191
qHTS for Inhibitors of TGF-b	TGFB1	inflammatory bowel disease	pathwayBased	403345	4970	0.255444106574039	1009
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	inflammatory bowel disease	targetBased	394050	3624	0.47424467902973	338
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	inflammatory bowel disease	targetBased	67275	2509	0.429537177851221	1828
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	inflammatory bowel disease	targetBased	335239	991	0.450159732473526	26
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	inflammatory bowel disease	targetBased	335239	695	0.450159732473526	26
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	inflammatory bowel disease	targetBased	326888	645	0.539973454347842	88
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	inflammatory bowel disease	targetBased	75924	1804	0.316933224547464	53
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	inflammatory bowel disease	targetBased	363803	458	0.429840930588652	33
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	inflammatory bowel disease	targetBased	217959	771	0.263404934707527	29
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	inflammatory bowel disease	targetBased	217959	569	0.263404934707527	29
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inflammatory bowel disease	targetBased	99314	335	0.593795823724006	632
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inflammatory bowel disease	targetBased	196176	782	0.593795823724006	632
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inflammatory bowel disease	targetBased	99314	390	0.593795823724006	632
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inflammatory bowel disease	targetBased	196177	811	0.593795823724006	632
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inflammatory bowel disease	targetBased	196176	670	0.593795823724006	632
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inflammatory bowel disease	targetBased	196177	519	0.593795823724006	632
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	inflammatory bowel disease	targetBased	304060	10600	0.401130853590169	81
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	inflammatory bowel disease	pathwayBased	7671	874	0.401130853590169	81
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	inflammatory bowel disease	pathwayBased	305439	16717	0.401130853590169	81
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	inflammatory bowel disease	targetBased	369953	3080	0.274356875163875	282
uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase	ALPI_inhibitors	inflammatory bowel disease	targetBased	330392	393	0.551025850997796	30
uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase	ALPI_inhibitors	inflammatory bowel disease	targetBased	331670	664	0.551025850997796	30
Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase	ALPI_activators	inflammatory bowel disease	targetBased	195570	326	0.551025850997796	30
uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase	ALPI_activators	inflammatory bowel disease	targetBased	330392	537	0.551025850997796	30
uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase	ALPI_activators	inflammatory bowel disease	targetBased	331670	785	0.551025850997796	30
HTS of Smad transcription factor inhibitors	SMAD3	inflammatory bowel disease	targetBased	88033	251	0.532992751133878	89
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	inflammatory bowel disease	targetBased	292323	1836	0.703692814590368	1872
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	inflammatory bowel disease	pathwayBased	194666	1772	0.426166728756354	892
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	inflammatory bowel disease	pathwayBased	194666	1722	0.426166728756354	892
OTUD3 deubiquitinase inhibition: Primary qHTS	OTUD3	inflammatory bowel disease	targetBased	47480	334	0.32166348562018	32
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	inflammatory bowel disease	targetBased	55710	315	0.28469229931646	111
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	inflammatory bowel disease	targetBased	325247	1021	0.400162717303332	25
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	chronic progressive multiple sclerosis	targetBased	55710	315	0.538635520397193	20
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	seasonal allergic rhinitis	pathwayBased	64908	979	0.448820053202874	8
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	seasonal allergic rhinitis	pathwayBased	64908	278	0.448820053202874	8
qHTS of IL-2 Activators	IL2	seasonal allergic rhinitis	targetBased	364617	238	0.332747471857003	11
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	seasonal allergic rhinitis	targetBased	75924	1804	0.43297757656177	17
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	seasonal allergic rhinitis	targetBased	359207	1189	0.620287278383327	14
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	seasonal allergic rhinitis	targetBased	63676	1938	0.620287278383327	14
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	seasonal allergic rhinitis	targetBased	359207	316	0.620287278383327	14
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	seasonal allergic rhinitis	targetBased	63656	2179	0.620287278383327	14
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	seasonal allergic rhinitis	targetBased	359207	4555	0.620287278383327	14
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	seasonal allergic rhinitis	targetBased	339297	1446	0.581326863490048	9
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Vitiligo	targetBased	217959	2390	0.417884831049486	32
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	relapsing-remitting multiple sclerosis	targetBased	336894	489	0.64736606261308	54
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	relapsing-remitting multiple sclerosis	targetBased	394050	3624	0.303701503622198	12
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	relapsing-remitting multiple sclerosis	targetBased	326888	645	0.64002439670588	53
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	relapsing-remitting multiple sclerosis	targetBased	217959	771	0.64372552302434	48
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	relapsing-remitting multiple sclerosis	targetBased	217959	569	0.64372552302434	48
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	relapsing-remitting multiple sclerosis	targetBased	55710	315	0.655930591244198	144
Primary HTS Assay for S1P3 Antagonists	S1PR3	relapsing-remitting multiple sclerosis	targetBased	169141	462	0.643752814149123	48
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	relapsing-remitting multiple sclerosis	targetBased	96879	447	0.643347103603292	47
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	relapsing-remitting multiple sclerosis	targetBased	96879	207	0.643347103603292	47
Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3	procaspase3Activators	mucocutaneous lymph node syndrome	targetBased	326024	350	0.495035722399972	65
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	acute graft vs. host disease	targetBased	217959	2390	0.515680643226986	9
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Myasthenia gravis	targetBased	305610	3878	0.628049159950515	18
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Myasthenia gravis	targetBased	305610	1082	0.628049159950515	18
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Myasthenia gravis	targetBased	305610	1552	0.628049159950515	18
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Myasthenia gravis	targetBased	343666	1267	0.628049159950515	18
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Myasthenia gravis	targetBased	342084	3260	0.628049159950515	18
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	Myasthenia gravis	targetBased	305609	3405	0.628049159950515	18
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	Myasthenia gravis	targetBased	305600	1644	0.628049159950515	18
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	autoimmune disease	targetBased	217959	2390	0.284976181084817	328
Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE)	SIAE	autoimmune disease	targetBased	369933	2555	0.70498382256379	32
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	autoimmune disease	targetBased	394050	3624	0.26935989249464	558
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	autoimmune disease	targetBased	67275	2509	0.259092984642321	3018
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	autoimmune disease	targetBased	326888	645	0.33909468052582	139
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	autoimmune disease	targetBased	99314	335	0.461685404329151	534
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	autoimmune disease	targetBased	196176	782	0.461685404329151	534
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	autoimmune disease	targetBased	99314	390	0.461685404329151	534
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	autoimmune disease	targetBased	196177	811	0.461685404329151	534
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	autoimmune disease	targetBased	196176	670	0.461685404329151	534
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	autoimmune disease	targetBased	196177	519	0.461685404329151	534
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	autoimmune disease	targetBased	369953	3080	0.267975631196369	285
uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)	p47phoxInhibitors	autoimmune disease	targetBased	217454	1142	0.313808795263764	79
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS)	PADI4	autoimmune disease	targetBased	326022	1334	0.424809734170857	159
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	autoimmune disease	targetBased	329153	670	0.270604544732409	1003
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	autoimmune disease	targetBased	329153	670	0.270604544732409	1003
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	autoimmune disease	targetBased	72026	352	0.270604544732409	1003
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	autoimmune disease	targetBased	72026	1794	0.270604544732409	1003
HTS of Smad transcription factor inhibitors	SMAD3	autoimmune disease	targetBased	88033	251	0.427740335161443	100
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	autoimmune disease	targetBased	292323	1836	0.322850001488186	1212
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	autoimmune disease	pathwayBased	194666	1772	0.897704362357904	1295
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	autoimmune disease	pathwayBased	194666	1722	0.897704362357904	1295
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	autoimmune disease	targetBased	128695	1039	0.568589520918476	192
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	autoimmune disease	targetBased	127961	1153	0.568589520918476	192
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	proctitis	targetBased	99314	335	0.583175100421059	9
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	proctitis	targetBased	196176	782	0.583175100421059	9
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	proctitis	targetBased	99314	390	0.583175100421059	9
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	proctitis	targetBased	196177	811	0.583175100421059	9
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	proctitis	targetBased	196176	670	0.583175100421059	9
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	proctitis	targetBased	196177	519	0.583175100421059	9
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	small bowel Crohn's disease	targetBased	292323	1836	0.286105916237584	14
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	allergic rhinitis	pathwayBased	64908	979	0.485483319847018	22
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	allergic rhinitis	pathwayBased	64908	278	0.485483319847018	22
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	allergic rhinitis	targetBased	290726	671	0.332353881234872	7
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	allergic rhinitis	pathwayBased	193265	3100	0.447576648851219	199
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	allergic rhinitis	pathwayBased	359244	3094	0.447576648851219	199
qHTS of IL-2 Activators	IL2	allergic rhinitis	targetBased	364617	238	0.320282297274405	152
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	allergic rhinitis	targetBased	75924	1804	0.535980475306307	47
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	allergic rhinitis	pathwayBased	362051	17187	0.386445309864048	181
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	allergic rhinitis	targetBased	304060	10600	0.30110251368226	17
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	allergic rhinitis	pathwayBased	7671	874	0.30110251368226	17
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	allergic rhinitis	pathwayBased	305439	16717	0.30110251368226	17
qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15_inhibitors	allergic rhinitis	targetBased	73174	1034	0.411026948368507	11
HTS of Smad transcription factor inhibitors	SMAD3	allergic rhinitis	targetBased	88033	251	0.532859659476675	20
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	allergic rhinitis	targetBased	359207	1189	0.627077400922343	17
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	allergic rhinitis	targetBased	63676	1938	0.627077400922343	17
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	allergic rhinitis	targetBased	359207	316	0.627077400922343	17
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	allergic rhinitis	targetBased	63656	2179	0.627077400922343	17
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	allergic rhinitis	targetBased	359207	4555	0.627077400922343	17
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	allergic rhinitis	targetBased	339297	1446	0.548658639799238	14
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	allergic rhinitis	targetBased	316642	617	0.427563036899599	34
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	lupus nephritis	targetBased	316642	617	0.368678188787264	6
qHTS assay for re-activators of p53 using a Luc reporter	TP53	lymphatic system disease	pathwayBased	321427	201	0.293285626205835	1400
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphatic system disease	targetBased	54509	528	0.293285626205835	1400
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphatic system disease	targetBased	54513	338	0.293285626205835	1400
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphatic system disease	targetBased	125394	1890	0.293285626205835	1400
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphatic system disease	targetBased	124022	1156	0.293285626205835	1400
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	lymphatic system disease	targetBased	325630	216	0.277557010338014	91
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	interleukin 1 receptor-like 1 measurement	targetBased	75924	1804	0.516816961193787	14
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	interleukin 18 receptor 1 measurement	targetBased	75924	1804	0.346397165145154	11
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	secondary progressive multiple sclerosis	targetBased	55710	315	0.487644718997637	42
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	chronic inflammatory demyelinating polyneuropathy	targetBased	42576	834	0.634841225279261	45
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	STAT3 gain of function	pathwayBased	194666	1772	0.606952560260641	770
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	STAT3 gain of function	pathwayBased	194666	1722	0.606952560260641	770
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	neuroinflammatory disorder	targetBased	305610	1552	0.428791740822698	18
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	neuroinflammatory disorder	targetBased	343666	1267	0.428791740822698	18
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	neuroinflammatory disorder	targetBased	342084	3260	0.428791740822698	18
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	neuroinflammatory disorder	pathwayBased	70898	707	0.395913906802846	7
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	neuroinflammatory disorder	pathwayBased	131324	544	0.395913906802846	7
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	neuroinflammatory disorder	pathwayBased	193265	3100	0.412009492152627	161
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	neuroinflammatory disorder	pathwayBased	359244	3094	0.412009492152627	161
qHTS for Inhibitors of TGF-b	TGFB1	inflammatory bowel disease, immunodeficiency, and encephalopathy	pathwayBased	403345	4970	0.752376428542243	30
Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation	WEE1	neuroinflammatory disorder	targetBased	217959	2616	0.424632003390909	9
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	neuroinflammatory disorder	pathwayBased	194666	1772	0.465852538787439	39
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	neuroinflammatory disorder	pathwayBased	194666	1722	0.465852538787439	39
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	neuroinflammatory disorder	targetBased	339297	1446	0.303641809113339	7
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	neuroinflammatory disorder	targetBased	369953	1596	0.362258189767571	7
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	neuroinflammatory disorder	pathwayBased	43989	342	0.450938815833541	24
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	systemic inflammatory response syndrome	pathwayBased	362051	17187	0.297340349354546	203
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	macrophage activation syndrome	targetBased	67275	2509	0.307196122303397	131
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	psoriasis vulgaris	targetBased	394050	3624	0.655284149899379	86
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	monogenic diabetes	targetBased	356160	3470	0.443040939126801	18
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	monogenic diabetes	targetBased	356160	1703	0.443040939126801	18
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	monogenic diabetes	targetBased	128695	1039	0.723854062699688	131
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	monogenic diabetes	targetBased	127961	1153	0.723854062699688	131
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	hypersensitivity reaction disease	targetBased	217959	2390	0.268730617640425	213
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	Inflammatory abnormality of the skin	targetBased	330392	1295	0.296789047816734	55
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	Immunodeficiency	targetBased	322361	619	0.374658619756015	36
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	Immunodeficiency	targetBased	347933	673	0.507538257966889	8
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	Combined immunodeficiency	pathwayBased	195980	5134	0.509775695278464	11
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	Combined immunodeficiency	targetBased	195980	695	0.509775695278464	11
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	Combined immunodeficiency	targetBased	30104	235	0.509686858131481	33
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	Amyotrophic lateral sclerosis	targetBased	385746	932	0.411659407127753	675
qHTS of TDP-43 Inhibitors	TARDBP	Amyotrophic lateral sclerosis	pathwayBased	403703	7150	0.42662742198745	2529
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	Amyotrophic lateral sclerosis	pathwayBased	45163	203	0.42662742198745	2529
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	Amyotrophic lateral sclerosis	targetBased	217959	923	0.411250221903632	149
HCS assay for microtubule stabilizers	TUBB	neutropenia	targetBased	195821	1625	0.429115894771016	18
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	hyper-IgM syndrome	targetBased	90878	289	0.41140906059619	148
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	allergic asthma	targetBased	339297	1446	0.305785418457101	20
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	inborn error of immunity	pathwayBased	193265	3100	0.567222711159724	483
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	inborn error of immunity	pathwayBased	359244	3094	0.567222711159724	483
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	inborn error of immunity	targetBased	67275	2509	0.260508250524808	558
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	inborn error of immunity	targetBased	90878	289	0.35263597806567	286
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	inborn error of immunity	pathwayBased	195980	5134	0.323072945633956	978
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	inborn error of immunity	targetBased	195980	695	0.323072945633956	978
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	inborn error of immunity	targetBased	92518	501	0.321548150235644	156
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	inborn error of immunity	pathwayBased	194666	1772	0.309008733126974	490
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	inborn error of immunity	pathwayBased	194666	1722	0.309008733126974	490
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	allergic disease	pathwayBased	64908	979	0.451288505056579	24
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	allergic disease	pathwayBased	64908	278	0.451288505056579	24
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	allergic disease	targetBased	290355	265	0.511316437424948	6
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	allergic disease	pathwayBased	193265	3100	0.403052761694357	225
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	allergic disease	pathwayBased	359244	3094	0.403052761694357	225
qHTS of IL-2 Activators	IL2	allergic disease	targetBased	364617	238	0.343320178641678	170
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	allergic disease	targetBased	394050	3624	0.255964635028286	34
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	allergic disease	targetBased	335239	991	0.554877973171716	8
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	allergic disease	targetBased	335239	695	0.554877973171716	8
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	allergic disease	targetBased	75924	1804	0.518691103234877	71
qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15_inhibitors	allergic disease	targetBased	73174	1034	0.33358317257055	14
HTS of Smad transcription factor inhibitors	SMAD3	allergic disease	targetBased	88033	251	0.540851322143723	28
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	allergic disease	targetBased	339297	1446	0.628446114609922	34
HCS assay for microtubule stabilizers	TUBB	allergic disease	targetBased	195821	1625	0.392468604405345	6
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	multiple sclerosis	targetBased	305610	3878	0.645235750885557	44
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	multiple sclerosis	targetBased	305610	1082	0.645235750885557	44
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	multiple sclerosis	targetBased	305610	1552	0.645235750885557	44
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	multiple sclerosis	targetBased	343666	1267	0.645235750885557	44
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	multiple sclerosis	targetBased	342084	3260	0.645235750885557	44
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	multiple sclerosis	targetBased	305609	3405	0.645235750885557	44
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	multiple sclerosis	targetBased	305600	1644	0.645235750885557	44
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	multiple sclerosis	targetBased	336894	489	0.690530836424373	76
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	multiple sclerosis	targetBased	290355	265	0.284952492325572	8
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	multiple sclerosis	targetBased	86095	1442	0.304265510825839	41
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	multiple sclerosis	targetBased	86095	1151	0.304265510825839	41
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	multiple sclerosis	targetBased	217959	2390	0.301837416904597	11
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	multiple sclerosis	targetBased	394050	3624	0.583926180418581	160
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	multiple sclerosis	targetBased	326888	645	0.645671851693653	110
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	multiple sclerosis	targetBased	217959	771	0.653518109271019	73
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	multiple sclerosis	targetBased	217959	569	0.653518109271019	73
qHTS assay for re-activators of p53 using a Luc reporter	TP53	multiple sclerosis	pathwayBased	321427	201	0.511922137474039	26
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	multiple sclerosis	targetBased	54509	528	0.511922137474039	26
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	multiple sclerosis	targetBased	54513	338	0.511922137474039	26
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	multiple sclerosis	targetBased	125394	1890	0.511922137474039	26
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	multiple sclerosis	targetBased	124022	1156	0.511922137474039	26
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	multiple sclerosis	targetBased	356517	1139	0.284450608994791	52
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	multiple sclerosis	targetBased	108286	1415	0.602040251565065	19
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	multiple sclerosis	targetBased	322361	619	0.330567104836404	30
Fluorescence polarization assay for PLK1 inhibitors	PLK1	multiple sclerosis	targetBased	97099	518	0.577168330395272	6
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	multiple sclerosis	targetBased	364065	10181	0.577168330395272	6
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	multiple sclerosis	pathwayBased	194666	1772	0.464976182091521	78
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	multiple sclerosis	pathwayBased	194666	1722	0.464976182091521	78
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	multiple sclerosis	targetBased	55710	315	0.664837114041353	511
S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity	S100A4	multiple sclerosis	targetBased	352235	501	0.388943152731707	6
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	multiple sclerosis	targetBased	316642	617	0.527972301614307	14
uHTS identification of small molecule modulators of NR3A	GRIN3A	multiple sclerosis	targetBased	339772	8480	0.554511094041346	18
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	multiple sclerosis	pathwayBased	43989	342	0.513718581157192	56
Primary HTS Assay for S1P3 Antagonists	S1PR3	multiple sclerosis	targetBased	169141	462	0.655299992173261	82
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	multiple sclerosis	targetBased	96879	447	0.657352493094362	83
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	multiple sclerosis	targetBased	96879	207	0.657352493094362	83
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	leukocyte adhesion deficiency 1	targetBased	92518	501	0.846366489681156	1155
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	hyper-IgE recurrent infection syndrome 1, autosomal dominant	pathwayBased	194666	1772	0.882249492479488	959
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	hyper-IgE recurrent infection syndrome 1, autosomal dominant	pathwayBased	194666	1722	0.882249492479488	959
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	immune deficiency disease	pathwayBased	195980	5134	0.316021335076101	957
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	immune deficiency disease	targetBased	195980	695	0.316021335076101	957
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	Omenn syndrome	targetBased	30104	235	0.773255884585553	42
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	hyper-IgM syndrome type 2	targetBased	90878	289	0.879623212791959	387
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	graft versus host disease	targetBased	217959	2390	0.624473599370751	132
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	graft versus host disease	targetBased	359207	1432	0.329151702280302	47
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	graft versus host disease	targetBased	359244	2975	0.289620981036984	8
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	graft versus host disease	targetBased	59788	212	0.530616370782023	24
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	graft versus host disease	targetBased	343468	734	0.287495758286774	32
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	combined immunodeficiency	pathwayBased	195980	5134	0.6056619781946	71
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	combined immunodeficiency	targetBased	195980	695	0.6056619781946	71
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	combined immunodeficiency	targetBased	322361	619	0.317197697603538	6424
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	combined immunodeficiency	targetBased	30104	235	0.647259809976761	700
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome	pathwayBased	195980	5134	0.894516532057074	815
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome	targetBased	195980	695	0.894516532057074	815
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	severe combined immunodeficiency	targetBased	30104	235	0.700962625675913	816
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	agammaglobulinemia	pathwayBased	193265	3100	0.300066410503025	179
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	agammaglobulinemia	pathwayBased	359244	3094	0.300066410503025	179
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	chronic mucocutaneous candidiasis	pathwayBased	195980	5134	0.611677577432826	289
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	chronic mucocutaneous candidiasis	targetBased	195980	695	0.611677577432826	289
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	hemophagocytic syndrome	targetBased	217959	2390	0.340446484450425	16
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	leukocyte adhesion deficiency	targetBased	92518	501	0.750707304739755	536
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	hyper-IgE syndrome	pathwayBased	194666	1772	0.791517184926309	530
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	hyper-IgE syndrome	pathwayBased	194666	1722	0.791517184926309	530
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	T-B- severe combined immunodeficiency	targetBased	30104	235	0.646206966714383	547
uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)	p47phoxInhibitors	chronic granulomatous disease	targetBased	217454	1142	0.707233849788776	336
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	22q11.2 deletion syndrome	targetBased	359518	300	0.413346187350415	9
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	22q11.2 deletion syndrome	targetBased	335652	1779	0.413346187350415	9
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	22q11.2 deletion syndrome	targetBased	362274	1056	0.413346187350415	9
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	22q11.2 deletion syndrome	targetBased	336308	6862	0.413346187350415	9
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	22q11.2 deletion syndrome	targetBased	357537	806	0.413346187350415	9
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	22q11.2 deletion syndrome	targetBased	339887	1178	0.413346187350415	9
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	autoimmune enteropathy	pathwayBased	195980	5134	0.300697343647726	276
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	autoimmune enteropathy	targetBased	195980	695	0.300697343647726	276
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	chronic graft versus host disease	targetBased	59788	212	0.327543716477058	35
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	immunodeficiency disease	pathwayBased	193265	3100	0.281553929492058	479
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	immunodeficiency disease	pathwayBased	359244	3094	0.281553929492058	479
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	immunodeficiency disease	pathwayBased	195980	5134	0.287801738691034	428
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	immunodeficiency disease	targetBased	195980	695	0.287801738691034	428
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	immunodeficiency disease	targetBased	30104	235	0.310321407554987	806
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	immunodeficiency disease	pathwayBased	194666	1772	0.315004903858155	857
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	immunodeficiency disease	pathwayBased	194666	1722	0.315004903858155	857
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	immunodeficiency 69	targetBased	67275	2509	0.503413308689518	8
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	T-B+ severe combined immunodeficiency	targetBased	30104	235	0.515494163057825	40
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	anaphylaxis	targetBased	339297	1446	0.582453837228469	12
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	immunodeficiency, developmental delay, and hypohomocysteinemia	targetBased	360873	7438	0.847171548352911	36
qHTS of Nrf2 Activators	Nrf2 activators	immunodeficiency, developmental delay, and hypohomocysteinemia	pathwayBased	403871	1243	0.847171548352911	36
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	Chronic mucocutaneous candidosis	pathwayBased	195980	5134	0.898378085302774	825
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	Chronic mucocutaneous candidosis	targetBased	195980	695	0.898378085302774	825
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	Autosomal dominant hyper-IgE syndrome	pathwayBased	194666	1772	0.882882834629081	1250
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	Autosomal dominant hyper-IgE syndrome	pathwayBased	194666	1722	0.882882834629081	1250
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	Primary hemophagocytic lymphohistiocytosis	targetBased	67275	2509	0.547474714183054	63
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	inflammation	targetBased	394050	3624	0.286397190264778	13
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inflammation	targetBased	99314	335	0.415910845994523	72
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inflammation	targetBased	196176	782	0.415910845994523	72
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inflammation	targetBased	99314	390	0.415910845994523	72
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inflammation	targetBased	196177	811	0.415910845994523	72
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inflammation	targetBased	196176	670	0.415910845994523	72
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	inflammation	targetBased	196177	519	0.415910845994523	72
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).	TPT1	Herpetic encephalitis	targetBased	302663	2452	0.28838130992472	6
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	Susceptibility to viral and mycobacterial infections	pathwayBased	195980	5134	0.849381507517208	756
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	Susceptibility to viral and mycobacterial infections	targetBased	195980	695	0.849381507517208	756
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	Familial cold urticaria	targetBased	330392	1295	0.798662521910481	38
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	Leukocyte adhesion deficiency type I	targetBased	92518	501	0.840099916485533	65
HTS of Smad transcription factor inhibitors	SMAD3	Familial hemophagocytic lymphohistiocytosis	targetBased	88033	251	0.392017533166542	8
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	type II hypersensitivity reaction disease	targetBased	217959	2390	0.267384674774844	170
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	type II hypersensitivity reaction disease	pathwayBased	195980	5134	0.302045298918466	408
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	type II hypersensitivity reaction disease	targetBased	195980	695	0.302045298918466	408
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	type II hypersensitivity reaction disease	targetBased	292323	1836	0.314700577014956	687
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	type II hypersensitivity reaction disease	targetBased	128695	1039	0.252318308693775	686
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	type II hypersensitivity reaction disease	targetBased	127961	1153	0.252318308693775	686
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	lymphatic system disease	targetBased	359207	1432	0.256421443619648	118
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	lymphatic system disease	pathwayBased	70898	707	0.261338183572329	27
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	lymphatic system disease	pathwayBased	131324	544	0.261338183572329	27
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	lymphatic system disease	targetBased	57013	201	0.258343187398969	363
qHTS Assay for NPC1 Promoter Activators	NPC1	lymphatic system disease	pathwayBased	320682	7575	0.303994030836414	1315
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	lymphatic system disease	targetBased	322361	619	0.286395979852275	244
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	lymphatic system disease	targetBased	194628	267	0.270951962053554	24
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	lymphatic system disease	targetBased	194152	656	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	lymphatic system disease	targetBased	194152	1288	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	lymphatic system disease	targetBased	194152	814	0.307418870150215	258
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	hypersensitivity reaction disease	pathwayBased	195980	5134	0.302054926818412	443
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	hypersensitivity reaction disease	targetBased	195980	695	0.302054926818412	443
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	hypersensitivity reaction disease	targetBased	292323	1836	0.314702437973755	696
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	hypersensitivity reaction disease	targetBased	359207	1189	0.250619928589118	12
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	hypersensitivity reaction disease	targetBased	63676	1938	0.250619928589118	12
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	hypersensitivity reaction disease	targetBased	359207	316	0.250619928589118	12
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	hypersensitivity reaction disease	targetBased	63656	2179	0.250619928589118	12
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	hypersensitivity reaction disease	targetBased	359207	4555	0.250619928589118	12
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	hypersensitivity reaction disease	targetBased	128695	1039	0.252347407467467	688
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	hypersensitivity reaction disease	targetBased	127961	1153	0.252347407467467	688
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Abnormality of the immune system	targetBased	217959	2390	0.250738061112055	218
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	autoimmune disorder of gastrointestinal tract	pathwayBased	195980	5134	0.300515512262878	317
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	autoimmune disorder of gastrointestinal tract	targetBased	195980	695	0.300515512262878	317
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	autoimmune disorder of gastrointestinal tract	targetBased	128695	1039	0.252080447239734	669
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	autoimmune disorder of gastrointestinal tract	targetBased	127961	1153	0.252080447239734	669
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	B cell deficiency	pathwayBased	193265	3100	0.278059242305738	204
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	B cell deficiency	pathwayBased	359244	3094	0.278059242305738	204
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	B cell deficiency	targetBased	90878	289	0.293415424309692	203
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	B cell deficiency	pathwayBased	194666	1772	0.302045929993097	412
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	B cell deficiency	pathwayBased	194666	1722	0.302045929993097	412
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	hyperimmunoglobulin syndrome	targetBased	90878	289	0.293054070786579	147
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	hyperimmunoglobulin syndrome	pathwayBased	194666	1772	0.302015873224594	392
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	hyperimmunoglobulin syndrome	pathwayBased	194666	1722	0.302015873224594	392
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	inborn error of immunity	targetBased	330392	1295	0.266884082183738	47
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	leukocyte disorder	targetBased	359207	1432	0.265940944674663	211
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	leukocyte disorder	targetBased	57013	201	0.274948506767873	418
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	leukocyte disorder	pathwayBased	193265	3100	0.281347845545978	1325
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	leukocyte disorder	pathwayBased	359244	3094	0.281347845545978	1325
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	leukocyte disorder	targetBased	90878	289	0.293880056330526	368
qHTS assay for re-activators of p53 using a Luc reporter	TP53	leukocyte disorder	pathwayBased	321427	201	0.293944069536877	1499
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	leukocyte disorder	targetBased	54509	528	0.293944069536877	1499
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	leukocyte disorder	targetBased	54513	338	0.293944069536877	1499
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	leukocyte disorder	targetBased	125394	1890	0.293944069536877	1499
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	leukocyte disorder	targetBased	124022	1156	0.293944069536877	1499
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	leukocyte disorder	targetBased	322361	619	0.289127425827789	314
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	leukocyte disorder	targetBased	92518	501	0.29708712507018	546
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	leukocyte disorder	pathwayBased	194666	1772	0.315033846306356	958
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	leukocyte disorder	pathwayBased	194666	1722	0.315033846306356	958
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	immune deficiency disease	pathwayBased	193265	3100	0.282900280866123	400
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	immune deficiency disease	pathwayBased	359244	3094	0.282900280866123	400
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	immune deficiency disease	targetBased	90878	289	0.293434735083632	275
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	immune deficiency disease	targetBased	92518	501	0.280530062736223	151
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	immune deficiency disease	targetBased	330392	1295	0.266884082183738	47
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	immune deficiency disease	pathwayBased	194666	1772	0.302049368982857	458
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	immune deficiency disease	pathwayBased	194666	1722	0.302049368982857	458
qHTS Assay for NPC1 Promoter Activators	NPC1	non-Langerhans cell histiocytosis	pathwayBased	320682	7575	0.303994027521701	1314
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	syndromic agammaglobulinemia	pathwayBased	193265	3100	0.278029312774993	118
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	syndromic agammaglobulinemia	pathwayBased	359244	3094	0.278029312774993	118
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	functional neutrophil defect	targetBased	92518	501	0.296879875982787	441
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	primary lymphedema	targetBased	194152	656	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	primary lymphedema	targetBased	194152	1288	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	primary lymphedema	targetBased	194152	814	0.307418870150215	258
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	lymphedema	targetBased	194152	656	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	lymphedema	targetBased	194152	1288	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	lymphedema	targetBased	194152	814	0.307418870150215	258
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	lymphatic malformation	targetBased	194152	656	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	lymphatic malformation	targetBased	194152	1288	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	lymphatic malformation	targetBased	194152	814	0.307418870150215	258
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	microcephaly, growth restriction and increased sister chromatid exchange	targetBased	347933	673	0.312126707883687	1978
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	immunodeficiency disease	targetBased	90878	289	0.293439877042445	345
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	immunodeficiency disease	targetBased	322361	619	0.326988384067494	13299
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	lymphoid system disorder	targetBased	359207	1432	0.256421443619648	118
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	lymphoid system disorder	pathwayBased	70898	707	0.261338183572329	27
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	lymphoid system disorder	pathwayBased	131324	544	0.261338183572329	27
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	lymphoid system disorder	targetBased	57013	201	0.258343187398969	363
qHTS Assay for NPC1 Promoter Activators	NPC1	lymphoid system disorder	pathwayBased	320682	7575	0.303994030836414	1315
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	lymphoid system disorder	targetBased	322361	619	0.286395979852275	244
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	lymphoid system disorder	targetBased	194628	267	0.270955346870825	25
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	lymphoid system disorder	targetBased	194152	656	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	lymphoid system disorder	targetBased	194152	1288	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	lymphoid system disorder	targetBased	194152	814	0.307418870150215	258
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	familial severe combined immunodeficiency	targetBased	30104	235	0.30736672335538	539
qHTS assay for re-activators of p53 using a Luc reporter	TP53	lymphoid system disorder	pathwayBased	321427	201	0.28981872771125	1409
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoid system disorder	targetBased	54509	528	0.28981872771125	1409
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoid system disorder	targetBased	54513	338	0.28981872771125	1409
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoid system disorder	targetBased	125394	1890	0.28981872771125	1409
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lymphoid system disorder	targetBased	124022	1156	0.28981872771125	1409
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	Primary immunodeficiency due to a defect in innate immunity	pathwayBased	195980	5134	0.308814750112337	560
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	Primary immunodeficiency due to a defect in innate immunity	targetBased	195980	695	0.308814750112337	560
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	Primary immunodeficiency due to a defect in innate immunity	targetBased	92518	501	0.280428462857787	42
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	Primary immunodeficiency due to a defect in innate immunity	targetBased	330392	1295	0.266507580720034	22
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	Genetic susceptibility to infections due to particular pathogens	pathwayBased	195980	5134	0.308738055196523	545
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	Genetic susceptibility to infections due to particular pathogens	targetBased	195980	695	0.308738055196523	545
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	DNA repair defect other than combined T-cell and B-cell immunodeficiencies	targetBased	322361	619	0.321645326286388	6829
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	Genetic immune deficiency with skin involvement	pathwayBased	195980	5134	0.299233459881725	277
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	Genetic immune deficiency with skin involvement	targetBased	195980	695	0.299233459881725	277
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	Genetic immune deficiency with skin involvement	pathwayBased	194666	1772	0.294031557794827	422
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	Genetic immune deficiency with skin involvement	pathwayBased	194666	1722	0.294031557794827	422
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	Autoinflammatory syndrome with immune deficiency	targetBased	330392	1295	0.26595669758817	16

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd522a3-587e-44ab-9de3-a0fd079f2ffb	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd522a3-587e-44ab-9de3-a0fd079f2ffb	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd522a3-587e-44ab-9de3-a0fd079f2ffb	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd522a3-587e-44ab-9de3-a0fd079f2ffb	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd522a3-587e-44ab-9de3-a0fd079f2ffb	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd522a3-587e-44ab-9de3-a0fd079f2ffb	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f	1	GoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	ulcerative colitis	THALIDOMIDE	targetBased	3	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00720538	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	immune system disease	THALIDOMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AX02	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Crohn's disease	THALIDOMIDE	targetBased	3	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00720538	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Crohn's disease	THALIDOMIDE	targetBased	3	Terminated	27/02/2018	https://clinicaltrials.gov/study/NCT03221166	0.7	LoF	protect	Difficulty in recruiting subjects who meet the inclusion/exclusion criteria
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	appendicitis	MORPHINE	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00477061	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	appendicitis	MORPHINE	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00477061	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	immune system disease	MORPHINE	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02135055	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	immune system disease	MORPHINE	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02135055	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	allergic disease	MORPHINE	targetBased	4	Recruiting	05/09/2021	https://clinicaltrials.gov/study/NCT05073744	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	allergic disease	MORPHINE	targetBased	4	Recruiting	05/09/2021	https://clinicaltrials.gov/study/NCT05073744	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Arthropathy	MORPHINE	targetBased	4	Completed	16/12/2020	https://clinicaltrials.gov/study/NCT04574479	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Arthropathy	MORPHINE	targetBased	4	Completed	16/12/2020	https://clinicaltrials.gov/study/NCT04574479	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	22q11.2 deletion syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	22q11.2 deletion syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	22q11.2 deletion syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	22q11.2 deletion syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	22q11.2 deletion syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	22q11.2 deletion syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	22q11.2 deletion syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	allergic disease	PACLITAXEL	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00277043	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	allergic disease	DOCETAXEL	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00277043	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neutropenia	DOCETAXEL	targetBased	3	Completed	10/05/2017	https://clinicaltrials.gov/study/NCT02953340	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neutropenia	DOCETAXEL	targetBased	3	Active, not recruiting	23/10/2019	https://clinicaltrials.gov/study/NCT03294577	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Postpericardiotomy Syndrome	COLCHICINE	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00128427	0.7	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	rheumatoid arthritis	ACETAMINOPHEN	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00246168	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	rheumatoid arthritis	ACETAMINOPHEN	targetBased	4	Completed	26/07/2011	https://clinicaltrials.gov/study/NCT01382940	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	multiple sclerosis	ACETAMINOPHEN	targetBased	3	Completed	30/04/2019	https://clinicaltrials.gov/study/NCT03824938	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	multiple sclerosis	ACETAMINOPHEN	targetBased	3	Active, not recruiting	24/10/2017	https://clinicaltrials.gov/study/NCT03368664	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	multiple sclerosis	ACETAMINOPHEN	targetBased	4	Recruiting	25/09/2017	https://clinicaltrials.gov/study/NCT03424733	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	celiac disease	ACETAMINOPHEN	targetBased	4	Not yet recruiting	01/03/2024	https://clinicaltrials.gov/study/NCT06149507	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	lupus nephritis	ACETAMINOPHEN	targetBased	3	Active, not recruiting	10/08/2020	https://clinicaltrials.gov/study/NCT04221477	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	lupus nephritis	ACETAMINOPHEN	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00282347	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	relapsing-remitting multiple sclerosis	ACETAMINOPHEN	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02205489	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pemphigus	ACETAMINOPHEN	targetBased	3	Terminated	23/12/2015	https://clinicaltrials.gov/study/NCT02613910	0.7		protect	Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammation	PIOGLITAZONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01161394	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammation	PIOGLITAZONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01161394	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammation	PIOGLITAZONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01161394	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammation	PIOGLITAZONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01161394	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammation	PIOGLITAZONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01161394	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammation	PIOGLITAZONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01161394	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	rheumatoid arthritis	PIOGLITAZONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554853	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	rheumatoid arthritis	PIOGLITAZONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554853	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	rheumatoid arthritis	PIOGLITAZONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554853	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	rheumatoid arthritis	PIOGLITAZONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554853	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	rheumatoid arthritis	PIOGLITAZONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554853	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	rheumatoid arthritis	PIOGLITAZONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554853	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rheumatoid arthritis	FENTANYL	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00524160	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rheumatoid arthritis	FENTANYL	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00524160	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	inflammatory bowel disease	FENTANYL	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01934088	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	inflammatory bowel disease	FENTANYL	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01934088	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	lymphedema	FENTANYL	targetBased	4	Completed	26/03/2020	https://clinicaltrials.gov/study/NCT05332028	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	lymphedema	FENTANYL	targetBased	4	Completed	26/03/2020	https://clinicaltrials.gov/study/NCT05332028	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	ROSIGLITAZONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00567593	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	ROSIGLITAZONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00567593	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	ROSIGLITAZONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00567593	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	ROSIGLITAZONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00567593	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	ROSIGLITAZONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00567593	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	ROSIGLITAZONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00567593	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	rheumatoid arthritis	NALTREXONE	targetBased	4	Unknown status	01/03/2003	https://clinicaltrials.gov/study/NCT00908089	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rheumatoid arthritis	NALTREXONE	targetBased	4	Unknown status	01/03/2003	https://clinicaltrials.gov/study/NCT00908089	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rheumatoid arthritis	NALTREXONE	targetBased	4	Unknown status	01/03/2003	https://clinicaltrials.gov/study/NCT00908089	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	multiple sclerosis	NALTREXONE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00501696	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	multiple sclerosis	NALTREXONE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00501696	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	multiple sclerosis	NALTREXONE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00501696	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	multiple sclerosis	ESTRADIOL	targetBased	3	Unknown status	01/06/2005	https://clinicaltrials.gov/study/NCT00127075	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	multiple sclerosis	ESTRADIOL	targetBased	3	Unknown status	01/06/2005	https://clinicaltrials.gov/study/NCT00127075	0.7	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		multiple sclerosis	AMANTADINE	targetBased	3	Completed	18/07/2018	https://clinicaltrials.gov/study/NCT03567057	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		multiple sclerosis	AMANTADINE	targetBased	3	Completed	29/03/2018	https://clinicaltrials.gov/study/NCT03436199	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		multiple sclerosis	AMANTADINE	targetBased	3	Completed	04/10/2017	https://clinicaltrials.gov/study/NCT03185065	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	anaphylaxis	EPINEPHRINE	targetBased	4	Completed	09/12/2019	https://clinicaltrials.gov/study/NCT04207840	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	anaphylaxis	EPINEPHRINE	targetBased	4	Completed	24/11/2017	https://clinicaltrials.gov/study/NCT03366298	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	type III hypersensitivity reaction disease	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed35d7d-616c-43cd-9776-705821afc1f0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Arthropathy	EPINEPHRINE	targetBased	4	Completed	28/02/2017	https://clinicaltrials.gov/study/NCT03094663	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	allergic rhinitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed35d7d-616c-43cd-9776-705821afc1f0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	seasonal allergic rhinitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed35d7d-616c-43cd-9776-705821afc1f0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	seasonal allergic rhinitis	EPINEPHRINE	targetBased	3	Completed	20/07/2015	https://clinicaltrials.gov/study/NCT02478398	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Rhinitis, Allergic, Perennial	EPINEPHRINE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01700192	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	allergic disease	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b5282a9-b149-4f0a-978e-5adbf48ec8aa	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	allergic disease	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76462d55-5448-0fd0-e053-2991aa0aa49f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	allergic disease	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7664bb0d-dc1a-ca8b-e053-2991aa0ad627	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	allergic disease	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad07e9bf-cc81-4736-86c7-2b2de9386eb2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	allergic disease	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59dc8445-6cec-40f0-8bde-c23510293509	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	allergic disease	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59c1261b-0239-4b78-9349-b64cdce5ca5d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	allergic disease	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b7a4364-668d-4eb2-a20c-04adc35aabe4	1	GoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	relapsing-remitting multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	relapsing-remitting multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	relapsing-remitting multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	relapsing-remitting multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	relapsing-remitting multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01356940	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01356940	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00649792	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00649792	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00483652	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00483652	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01328379	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01328379	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	04/02/2014	https://clinicaltrials.gov/study/NCT02849782	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	04/02/2014	https://clinicaltrials.gov/study/NCT02849782	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00127530	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00127530	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00648908	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00648908	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01656148	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01656148	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02146534	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02146534	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01480076	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01480076	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02143167	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02143167	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06136728	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06136728	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00654927	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00654927	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02259361	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02259361	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02219932	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02219932	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e10b2d92-2824-4395-8883-6fd52c784aa4	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e10b2d92-2824-4395-8883-6fd52c784aa4	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01235221	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01235221	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01235221	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01235221	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01235221	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	04/02/2014	https://clinicaltrials.gov/study/NCT02849782	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	04/02/2014	https://clinicaltrials.gov/study/NCT02849782	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	04/02/2014	https://clinicaltrials.gov/study/NCT02849782	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02259361	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02259361	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02259361	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00654927	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00654927	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00654927	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06136728	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06136728	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06136728	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01480076	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01480076	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01480076	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01656148	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01656148	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01656148	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02143167	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02143167	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02143167	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02146534	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02146534	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02146534	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00649792	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00649792	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00649792	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02219932	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02219932	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02219932	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00127530	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00127530	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00127530	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01328379	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01328379	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01328379	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00648908	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00648908	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00648908	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00483652	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00483652	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00483652	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e10b2d92-2824-4395-8883-6fd52c784aa4	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e10b2d92-2824-4395-8883-6fd52c784aa4	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e10b2d92-2824-4395-8883-6fd52c784aa4	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01356940	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01356940	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01356940	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	primary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	primary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	primary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	primary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	primary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	primary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	primary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	secondary progressive multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	21/02/2014	https://clinicaltrials.gov/study/NCT02208050	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	relapsing-remitting multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	relapsing-remitting multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01328379	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01328379	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02143167	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02143167	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02219932	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02219932	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02259361	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Unknown status	01/11/2014	https://clinicaltrials.gov/study/NCT02259361	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01917019	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e10b2d92-2824-4395-8883-6fd52c784aa4	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e10b2d92-2824-4395-8883-6fd52c784aa4	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00127530	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00127530	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00654927	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00654927	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01480076	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01480076	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06136728	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Not yet recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT06136728	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02146534	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02146534	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01235221	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01235221	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=550eb76a-e4a6-4fa1-ad65-c0fd8b0ce783	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01656148	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01656148	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00648908	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00648908	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	04/02/2014	https://clinicaltrials.gov/study/NCT02849782	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	04/02/2014	https://clinicaltrials.gov/study/NCT02849782	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01356940	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01356940	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00483652	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00483652	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00649792	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	DALFAMPRIDINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00649792	0.7	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89eb4706-c347-4bb8-8f89-394dbdec5cd3	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89eb4706-c347-4bb8-8f89-394dbdec5cd3	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89eb4706-c347-4bb8-8f89-394dbdec5cd3	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89eb4706-c347-4bb8-8f89-394dbdec5cd3	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89eb4706-c347-4bb8-8f89-394dbdec5cd3	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89eb4706-c347-4bb8-8f89-394dbdec5cd3	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e6b0544-e75d-463a-bd61-517834b49f53	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e6b0544-e75d-463a-bd61-517834b49f53	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e6b0544-e75d-463a-bd61-517834b49f53	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e6b0544-e75d-463a-bd61-517834b49f53	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e6b0544-e75d-463a-bd61-517834b49f53	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e6b0544-e75d-463a-bd61-517834b49f53	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	12/12/2014	https://clinicaltrials.gov/study/NCT02093663	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	12/12/2014	https://clinicaltrials.gov/study/NCT02093663	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	12/12/2014	https://clinicaltrials.gov/study/NCT02093663	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	12/12/2014	https://clinicaltrials.gov/study/NCT02093663	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	12/12/2014	https://clinicaltrials.gov/study/NCT02093663	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	12/12/2014	https://clinicaltrials.gov/study/NCT02093663	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70adfac7-f8b7-405c-86aa-b1f30343d38b	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70adfac7-f8b7-405c-86aa-b1f30343d38b	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70adfac7-f8b7-405c-86aa-b1f30343d38b	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70adfac7-f8b7-405c-86aa-b1f30343d38b	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70adfac7-f8b7-405c-86aa-b1f30343d38b	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70adfac7-f8b7-405c-86aa-b1f30343d38b	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07e5ac9c-a5b2-42dc-84fa-963dbc51ba21	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07e5ac9c-a5b2-42dc-84fa-963dbc51ba21	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07e5ac9c-a5b2-42dc-84fa-963dbc51ba21	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07e5ac9c-a5b2-42dc-84fa-963dbc51ba21	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07e5ac9c-a5b2-42dc-84fa-963dbc51ba21	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07e5ac9c-a5b2-42dc-84fa-963dbc51ba21	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7951139c-b271-45a4-b523-34b23800917b	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7951139c-b271-45a4-b523-34b23800917b	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7951139c-b271-45a4-b523-34b23800917b	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7951139c-b271-45a4-b523-34b23800917b	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7951139c-b271-45a4-b523-34b23800917b	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7951139c-b271-45a4-b523-34b23800917b	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	17/01/2023	https://clinicaltrials.gov/study/NCT05992142	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	17/01/2023	https://clinicaltrials.gov/study/NCT05992142	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	17/01/2023	https://clinicaltrials.gov/study/NCT05992142	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	17/01/2023	https://clinicaltrials.gov/study/NCT05992142	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	17/01/2023	https://clinicaltrials.gov/study/NCT05992142	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	17/01/2023	https://clinicaltrials.gov/study/NCT05992142	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00737789	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00737789	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00737789	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00737789	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00737789	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00737789	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a3bff5-e652-4771-9bf7-3b6850423cc5	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a3bff5-e652-4771-9bf7-3b6850423cc5	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a3bff5-e652-4771-9bf7-3b6850423cc5	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a3bff5-e652-4771-9bf7-3b6850423cc5	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a3bff5-e652-4771-9bf7-3b6850423cc5	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a3bff5-e652-4771-9bf7-3b6850423cc5	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c076918-09c0-49bd-bb11-db1e011d597c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c076918-09c0-49bd-bb11-db1e011d597c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c076918-09c0-49bd-bb11-db1e011d597c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c076918-09c0-49bd-bb11-db1e011d597c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c076918-09c0-49bd-bb11-db1e011d597c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c076918-09c0-49bd-bb11-db1e011d597c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a7d8d3c-d407-4864-b305-e83c036fe98c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a7d8d3c-d407-4864-b305-e83c036fe98c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a7d8d3c-d407-4864-b305-e83c036fe98c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a7d8d3c-d407-4864-b305-e83c036fe98c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a7d8d3c-d407-4864-b305-e83c036fe98c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a7d8d3c-d407-4864-b305-e83c036fe98c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02522767	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02522767	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02522767	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02522767	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02522767	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02522767	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95de7015-932f-48d4-8734-5906aaee697e	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95de7015-932f-48d4-8734-5906aaee697e	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95de7015-932f-48d4-8734-5906aaee697e	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95de7015-932f-48d4-8734-5906aaee697e	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95de7015-932f-48d4-8734-5906aaee697e	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95de7015-932f-48d4-8734-5906aaee697e	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	22/12/2005	https://clinicaltrials.gov/study/NCT00326209	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	22/12/2005	https://clinicaltrials.gov/study/NCT00326209	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	22/12/2005	https://clinicaltrials.gov/study/NCT00326209	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	22/12/2005	https://clinicaltrials.gov/study/NCT00326209	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	22/12/2005	https://clinicaltrials.gov/study/NCT00326209	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	22/12/2005	https://clinicaltrials.gov/study/NCT00326209	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00577473	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00577473	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00577473	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00577473	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00577473	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00577473	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=370bd908-55af-4dfc-8837-913bf73babbd	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=370bd908-55af-4dfc-8837-913bf73babbd	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=370bd908-55af-4dfc-8837-913bf73babbd	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=370bd908-55af-4dfc-8837-913bf73babbd	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=370bd908-55af-4dfc-8837-913bf73babbd	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=370bd908-55af-4dfc-8837-913bf73babbd	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02368717	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02368717	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02368717	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02368717	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02368717	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02368717	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77140634-9f32-40ca-8c83-9fcc3e373c16	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77140634-9f32-40ca-8c83-9fcc3e373c16	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77140634-9f32-40ca-8c83-9fcc3e373c16	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77140634-9f32-40ca-8c83-9fcc3e373c16	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77140634-9f32-40ca-8c83-9fcc3e373c16	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77140634-9f32-40ca-8c83-9fcc3e373c16	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01257386	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01257386	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01257386	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01257386	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01257386	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01257386	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00744016	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00744016	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00744016	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00744016	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00744016	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00744016	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb5bcaab-0f86-4817-9373-0a5e5e1982d2	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb5bcaab-0f86-4817-9373-0a5e5e1982d2	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb5bcaab-0f86-4817-9373-0a5e5e1982d2	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb5bcaab-0f86-4817-9373-0a5e5e1982d2	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb5bcaab-0f86-4817-9373-0a5e5e1982d2	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb5bcaab-0f86-4817-9373-0a5e5e1982d2	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef12dce1-5259-40bf-84f3-2db4859c560b	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef12dce1-5259-40bf-84f3-2db4859c560b	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef12dce1-5259-40bf-84f3-2db4859c560b	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef12dce1-5259-40bf-84f3-2db4859c560b	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef12dce1-5259-40bf-84f3-2db4859c560b	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef12dce1-5259-40bf-84f3-2db4859c560b	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e11e41a1-56e3-4505-b3a5-159e03e2daba	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e11e41a1-56e3-4505-b3a5-159e03e2daba	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e11e41a1-56e3-4505-b3a5-159e03e2daba	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e11e41a1-56e3-4505-b3a5-159e03e2daba	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e11e41a1-56e3-4505-b3a5-159e03e2daba	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e11e41a1-56e3-4505-b3a5-159e03e2daba	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d31a6e7d-31b1-474e-bc7b-821b08115109	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d31a6e7d-31b1-474e-bc7b-821b08115109	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d31a6e7d-31b1-474e-bc7b-821b08115109	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d31a6e7d-31b1-474e-bc7b-821b08115109	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d31a6e7d-31b1-474e-bc7b-821b08115109	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d31a6e7d-31b1-474e-bc7b-821b08115109	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bdf3222-469c-44b0-bbcd-25faeaeff178	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bdf3222-469c-44b0-bbcd-25faeaeff178	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bdf3222-469c-44b0-bbcd-25faeaeff178	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bdf3222-469c-44b0-bbcd-25faeaeff178	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bdf3222-469c-44b0-bbcd-25faeaeff178	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bdf3222-469c-44b0-bbcd-25faeaeff178	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	30/09/2003	https://clinicaltrials.gov/study/NCT00503243	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	30/09/2003	https://clinicaltrials.gov/study/NCT00503243	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	30/09/2003	https://clinicaltrials.gov/study/NCT00503243	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	30/09/2003	https://clinicaltrials.gov/study/NCT00503243	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	30/09/2003	https://clinicaltrials.gov/study/NCT00503243	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	30/09/2003	https://clinicaltrials.gov/study/NCT00503243	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT00984568	0.7	GoF	protect	Due to slow recruitment the study was stopped prematurely.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT00984568	0.7	GoF	protect	Due to slow recruitment the study was stopped prematurely.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT00984568	0.7	GoF	protect	Due to slow recruitment the study was stopped prematurely.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT00984568	0.7	GoF	protect	Due to slow recruitment the study was stopped prematurely.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT00984568	0.7	GoF	protect	Due to slow recruitment the study was stopped prematurely.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Terminated	01/11/2009	https://clinicaltrials.gov/study/NCT00984568	0.7	GoF	protect	Due to slow recruitment the study was stopped prematurely.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00767728	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00767728	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00767728	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00767728	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00767728	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00767728	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	29/06/2010	https://clinicaltrials.gov/study/NCT01124149	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	29/06/2010	https://clinicaltrials.gov/study/NCT01124149	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	29/06/2010	https://clinicaltrials.gov/study/NCT01124149	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	29/06/2010	https://clinicaltrials.gov/study/NCT01124149	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	29/06/2010	https://clinicaltrials.gov/study/NCT01124149	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	29/06/2010	https://clinicaltrials.gov/study/NCT01124149	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a69ce2b9-2866-406d-a365-5b185a269e3e	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a69ce2b9-2866-406d-a365-5b185a269e3e	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a69ce2b9-2866-406d-a365-5b185a269e3e	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a69ce2b9-2866-406d-a365-5b185a269e3e	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a69ce2b9-2866-406d-a365-5b185a269e3e	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a69ce2b9-2866-406d-a365-5b185a269e3e	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01745770	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01745770	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01745770	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01745770	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01745770	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01745770	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02910245	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02910245	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02910245	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02910245	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02910245	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT02910245	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02280629	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02280629	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02280629	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02280629	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02280629	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02280629	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00343850	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00343850	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00343850	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00343850	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00343850	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00343850	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f68f68c-58d2-4575-b573-f2e62f95d7e3	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f68f68c-58d2-4575-b573-f2e62f95d7e3	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f68f68c-58d2-4575-b573-f2e62f95d7e3	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f68f68c-58d2-4575-b573-f2e62f95d7e3	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f68f68c-58d2-4575-b573-f2e62f95d7e3	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f68f68c-58d2-4575-b573-f2e62f95d7e3	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00652145	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00652145	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00652145	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00652145	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00652145	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00652145	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Recruiting	28/11/2019	https://clinicaltrials.gov/study/NCT04133194	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Recruiting	28/11/2019	https://clinicaltrials.gov/study/NCT04133194	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Recruiting	28/11/2019	https://clinicaltrials.gov/study/NCT04133194	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Recruiting	28/11/2019	https://clinicaltrials.gov/study/NCT04133194	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Recruiting	28/11/2019	https://clinicaltrials.gov/study/NCT04133194	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Recruiting	28/11/2019	https://clinicaltrials.gov/study/NCT04133194	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	02/03/2018	https://clinicaltrials.gov/study/NCT03412682	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	02/03/2018	https://clinicaltrials.gov/study/NCT03412682	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	02/03/2018	https://clinicaltrials.gov/study/NCT03412682	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	02/03/2018	https://clinicaltrials.gov/study/NCT03412682	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	02/03/2018	https://clinicaltrials.gov/study/NCT03412682	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	02/03/2018	https://clinicaltrials.gov/study/NCT03412682	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34494be6-3db5-4349-ab2d-57e8ccb383fc	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34494be6-3db5-4349-ab2d-57e8ccb383fc	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34494be6-3db5-4349-ab2d-57e8ccb383fc	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34494be6-3db5-4349-ab2d-57e8ccb383fc	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34494be6-3db5-4349-ab2d-57e8ccb383fc	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34494be6-3db5-4349-ab2d-57e8ccb383fc	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa273fdc-f7c4-4901-8f71-59ae03b8cdb1	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa273fdc-f7c4-4901-8f71-59ae03b8cdb1	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa273fdc-f7c4-4901-8f71-59ae03b8cdb1	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa273fdc-f7c4-4901-8f71-59ae03b8cdb1	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa273fdc-f7c4-4901-8f71-59ae03b8cdb1	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa273fdc-f7c4-4901-8f71-59ae03b8cdb1	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/12/2018	https://clinicaltrials.gov/study/NCT03716388	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/12/2018	https://clinicaltrials.gov/study/NCT03716388	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/12/2018	https://clinicaltrials.gov/study/NCT03716388	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/12/2018	https://clinicaltrials.gov/study/NCT03716388	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/12/2018	https://clinicaltrials.gov/study/NCT03716388	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/12/2018	https://clinicaltrials.gov/study/NCT03716388	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00713310	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00713310	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00713310	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00713310	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00713310	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00713310	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Not yet recruiting	15/09/2024	https://clinicaltrials.gov/study/NCT05316220	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Not yet recruiting	15/09/2024	https://clinicaltrials.gov/study/NCT05316220	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Not yet recruiting	15/09/2024	https://clinicaltrials.gov/study/NCT05316220	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Not yet recruiting	15/09/2024	https://clinicaltrials.gov/study/NCT05316220	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Not yet recruiting	15/09/2024	https://clinicaltrials.gov/study/NCT05316220	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Not yet recruiting	15/09/2024	https://clinicaltrials.gov/study/NCT05316220	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00167882	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00167882	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00167882	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00167882	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00167882	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00167882	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=743ada1c-0f04-43ea-be7d-1560164e6f6e	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=743ada1c-0f04-43ea-be7d-1560164e6f6e	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=743ada1c-0f04-43ea-be7d-1560164e6f6e	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=743ada1c-0f04-43ea-be7d-1560164e6f6e	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=743ada1c-0f04-43ea-be7d-1560164e6f6e	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=743ada1c-0f04-43ea-be7d-1560164e6f6e	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	26/11/2003	https://clinicaltrials.gov/study/NCT00151944	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	26/11/2003	https://clinicaltrials.gov/study/NCT00151944	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	26/11/2003	https://clinicaltrials.gov/study/NCT00151944	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	26/11/2003	https://clinicaltrials.gov/study/NCT00151944	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	26/11/2003	https://clinicaltrials.gov/study/NCT00151944	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	26/11/2003	https://clinicaltrials.gov/study/NCT00151944	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a666d21d-da21-498d-aea2-055326cafd70	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00446849	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00446849	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00446849	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00446849	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00446849	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00446849	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a97c3815-a0d5-4763-8c3f-9caa5dd9b01b	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a97c3815-a0d5-4763-8c3f-9caa5dd9b01b	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a97c3815-a0d5-4763-8c3f-9caa5dd9b01b	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a97c3815-a0d5-4763-8c3f-9caa5dd9b01b	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a97c3815-a0d5-4763-8c3f-9caa5dd9b01b	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a97c3815-a0d5-4763-8c3f-9caa5dd9b01b	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91da40ab-cfd7-4e2a-8ef9-84809176d850	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91da40ab-cfd7-4e2a-8ef9-84809176d850	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91da40ab-cfd7-4e2a-8ef9-84809176d850	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91da40ab-cfd7-4e2a-8ef9-84809176d850	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91da40ab-cfd7-4e2a-8ef9-84809176d850	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91da40ab-cfd7-4e2a-8ef9-84809176d850	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01257399	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01257399	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01257399	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01257399	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01257399	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01257399	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00505778	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00505778	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00505778	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00505778	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00505778	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00505778	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00092508	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00092508	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00092508	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00092508	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00092508	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00092508	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	13/06/2016	https://clinicaltrials.gov/study/NCT02665845	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	13/06/2016	https://clinicaltrials.gov/study/NCT02665845	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	13/06/2016	https://clinicaltrials.gov/study/NCT02665845	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	13/06/2016	https://clinicaltrials.gov/study/NCT02665845	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	13/06/2016	https://clinicaltrials.gov/study/NCT02665845	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	13/06/2016	https://clinicaltrials.gov/study/NCT02665845	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Not yet recruiting	01/03/2024	https://clinicaltrials.gov/study/NCT06176560	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Not yet recruiting	01/03/2024	https://clinicaltrials.gov/study/NCT06176560	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Not yet recruiting	01/03/2024	https://clinicaltrials.gov/study/NCT06176560	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Not yet recruiting	01/03/2024	https://clinicaltrials.gov/study/NCT06176560	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Not yet recruiting	01/03/2024	https://clinicaltrials.gov/study/NCT06176560	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Not yet recruiting	01/03/2024	https://clinicaltrials.gov/study/NCT06176560	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3479cbf1-434e-417f-be73-7c75139013f0	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3479cbf1-434e-417f-be73-7c75139013f0	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3479cbf1-434e-417f-be73-7c75139013f0	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3479cbf1-434e-417f-be73-7c75139013f0	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3479cbf1-434e-417f-be73-7c75139013f0	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3479cbf1-434e-417f-be73-7c75139013f0	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4ddf68d-1502-4242-89aa-c96436bdcbf6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4ddf68d-1502-4242-89aa-c96436bdcbf6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4ddf68d-1502-4242-89aa-c96436bdcbf6	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4ddf68d-1502-4242-89aa-c96436bdcbf6	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4ddf68d-1502-4242-89aa-c96436bdcbf6	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4ddf68d-1502-4242-89aa-c96436bdcbf6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83864c82-9114-4523-bab8-2b47beb88d4e	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83864c82-9114-4523-bab8-2b47beb88d4e	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83864c82-9114-4523-bab8-2b47beb88d4e	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83864c82-9114-4523-bab8-2b47beb88d4e	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83864c82-9114-4523-bab8-2b47beb88d4e	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83864c82-9114-4523-bab8-2b47beb88d4e	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00679432	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00679432	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00679432	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00679432	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00679432	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00679432	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Unknown status	01/05/2017	https://clinicaltrials.gov/study/NCT03110198	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Unknown status	01/05/2017	https://clinicaltrials.gov/study/NCT03110198	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Unknown status	01/05/2017	https://clinicaltrials.gov/study/NCT03110198	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Unknown status	01/05/2017	https://clinicaltrials.gov/study/NCT03110198	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Unknown status	01/05/2017	https://clinicaltrials.gov/study/NCT03110198	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Unknown status	01/05/2017	https://clinicaltrials.gov/study/NCT03110198	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00350415	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00350415	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00350415	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00350415	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00350415	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00350415	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00449722	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00449722	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00449722	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00449722	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00449722	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00449722	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24998e63-f01e-4a07-be5b-203aadd46941	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24998e63-f01e-4a07-be5b-203aadd46941	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24998e63-f01e-4a07-be5b-203aadd46941	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24998e63-f01e-4a07-be5b-203aadd46941	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24998e63-f01e-4a07-be5b-203aadd46941	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24998e63-f01e-4a07-be5b-203aadd46941	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	10/07/2012	https://clinicaltrials.gov/study/NCT01536535	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	10/07/2012	https://clinicaltrials.gov/study/NCT01536535	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	10/07/2012	https://clinicaltrials.gov/study/NCT01536535	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	10/07/2012	https://clinicaltrials.gov/study/NCT01536535	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	10/07/2012	https://clinicaltrials.gov/study/NCT01536535	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	10/07/2012	https://clinicaltrials.gov/study/NCT01536535	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfeede98-5520-4fd1-be02-4971453f9e24	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfeede98-5520-4fd1-be02-4971453f9e24	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfeede98-5520-4fd1-be02-4971453f9e24	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfeede98-5520-4fd1-be02-4971453f9e24	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfeede98-5520-4fd1-be02-4971453f9e24	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfeede98-5520-4fd1-be02-4971453f9e24	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d50f2c37-5675-49f3-bdd4-3b16d333ed40	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d50f2c37-5675-49f3-bdd4-3b16d333ed40	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d50f2c37-5675-49f3-bdd4-3b16d333ed40	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d50f2c37-5675-49f3-bdd4-3b16d333ed40	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d50f2c37-5675-49f3-bdd4-3b16d333ed40	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d50f2c37-5675-49f3-bdd4-3b16d333ed40	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3885d2c-8318-4aca-9b9c-c5a5ee847ed0	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3885d2c-8318-4aca-9b9c-c5a5ee847ed0	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3885d2c-8318-4aca-9b9c-c5a5ee847ed0	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3885d2c-8318-4aca-9b9c-c5a5ee847ed0	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3885d2c-8318-4aca-9b9c-c5a5ee847ed0	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3885d2c-8318-4aca-9b9c-c5a5ee847ed0	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02522780	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02522780	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02522780	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02522780	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02522780	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02522780	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5d05b1f-9f45-4f66-9f75-3c67934105de	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5d05b1f-9f45-4f66-9f75-3c67934105de	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5d05b1f-9f45-4f66-9f75-3c67934105de	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5d05b1f-9f45-4f66-9f75-3c67934105de	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5d05b1f-9f45-4f66-9f75-3c67934105de	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5d05b1f-9f45-4f66-9f75-3c67934105de	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT01004185	0.7	GoF	protect	Pediatric enrollment very slow.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT01004185	0.7	GoF	protect	Pediatric enrollment very slow.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT01004185	0.7	GoF	protect	Pediatric enrollment very slow.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT01004185	0.7	GoF	protect	Pediatric enrollment very slow.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT01004185	0.7	GoF	protect	Pediatric enrollment very slow.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT01004185	0.7	GoF	protect	Pediatric enrollment very slow.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	08/04/2005	https://clinicaltrials.gov/study/NCT00151892	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	08/04/2005	https://clinicaltrials.gov/study/NCT00151892	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	08/04/2005	https://clinicaltrials.gov/study/NCT00151892	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	08/04/2005	https://clinicaltrials.gov/study/NCT00151892	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	08/04/2005	https://clinicaltrials.gov/study/NCT00151892	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	08/04/2005	https://clinicaltrials.gov/study/NCT00151892	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d27a608-3ba1-4799-be38-c00fb08ce3ce	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d27a608-3ba1-4799-be38-c00fb08ce3ce	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d27a608-3ba1-4799-be38-c00fb08ce3ce	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d27a608-3ba1-4799-be38-c00fb08ce3ce	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d27a608-3ba1-4799-be38-c00fb08ce3ce	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d27a608-3ba1-4799-be38-c00fb08ce3ce	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f393841-42ef-46a4-a7b0-21cc59815912	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f393841-42ef-46a4-a7b0-21cc59815912	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f393841-42ef-46a4-a7b0-21cc59815912	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f393841-42ef-46a4-a7b0-21cc59815912	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f393841-42ef-46a4-a7b0-21cc59815912	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f393841-42ef-46a4-a7b0-21cc59815912	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba1e3bd4-fbe0-46a5-961e-167ccb09672c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba1e3bd4-fbe0-46a5-961e-167ccb09672c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba1e3bd4-fbe0-46a5-961e-167ccb09672c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba1e3bd4-fbe0-46a5-961e-167ccb09672c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba1e3bd4-fbe0-46a5-961e-167ccb09672c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba1e3bd4-fbe0-46a5-961e-167ccb09672c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01045018	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01045018	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01045018	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01045018	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01045018	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01045018	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	04/12/2003	https://clinicaltrials.gov/study/NCT00548574	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	04/12/2003	https://clinicaltrials.gov/study/NCT00548574	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	04/12/2003	https://clinicaltrials.gov/study/NCT00548574	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	04/12/2003	https://clinicaltrials.gov/study/NCT00548574	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	04/12/2003	https://clinicaltrials.gov/study/NCT00548574	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	04/12/2003	https://clinicaltrials.gov/study/NCT00548574	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00708656	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00708656	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00708656	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00708656	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00708656	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00708656	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3098a080-be86-4265-9818-7fc4beab77b7	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3098a080-be86-4265-9818-7fc4beab77b7	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3098a080-be86-4265-9818-7fc4beab77b7	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3098a080-be86-4265-9818-7fc4beab77b7	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3098a080-be86-4265-9818-7fc4beab77b7	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3098a080-be86-4265-9818-7fc4beab77b7	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4dbb01-3c0f-4217-8e33-e37263878828	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4dbb01-3c0f-4217-8e33-e37263878828	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4dbb01-3c0f-4217-8e33-e37263878828	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4dbb01-3c0f-4217-8e33-e37263878828	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4dbb01-3c0f-4217-8e33-e37263878828	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4dbb01-3c0f-4217-8e33-e37263878828	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00603733	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00603733	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00603733	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00603733	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00603733	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00603733	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec53b1d4-b98d-4b4d-acc3-199f98031966	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec53b1d4-b98d-4b4d-acc3-199f98031966	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec53b1d4-b98d-4b4d-acc3-199f98031966	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec53b1d4-b98d-4b4d-acc3-199f98031966	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec53b1d4-b98d-4b4d-acc3-199f98031966	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec53b1d4-b98d-4b4d-acc3-199f98031966	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Recruiting	15/01/2022	https://clinicaltrials.gov/study/NCT05205603	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Recruiting	15/01/2022	https://clinicaltrials.gov/study/NCT05205603	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Recruiting	15/01/2022	https://clinicaltrials.gov/study/NCT05205603	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Recruiting	15/01/2022	https://clinicaltrials.gov/study/NCT05205603	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Recruiting	15/01/2022	https://clinicaltrials.gov/study/NCT05205603	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Recruiting	15/01/2022	https://clinicaltrials.gov/study/NCT05205603	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac724f97-5941-47c1-bcc9-eb5e64be815a	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac724f97-5941-47c1-bcc9-eb5e64be815a	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac724f97-5941-47c1-bcc9-eb5e64be815a	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac724f97-5941-47c1-bcc9-eb5e64be815a	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac724f97-5941-47c1-bcc9-eb5e64be815a	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac724f97-5941-47c1-bcc9-eb5e64be815a	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d047e43-60c5-4d32-bd5e-204dee863afd	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d047e43-60c5-4d32-bd5e-204dee863afd	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d047e43-60c5-4d32-bd5e-204dee863afd	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d047e43-60c5-4d32-bd5e-204dee863afd	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d047e43-60c5-4d32-bd5e-204dee863afd	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d047e43-60c5-4d32-bd5e-204dee863afd	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01903252	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01903252	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01903252	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01903252	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01903252	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01903252	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00209300	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00209300	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00209300	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00209300	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00209300	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00209300	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d91179bf-48ce-423c-822d-cd06b60caabe	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d91179bf-48ce-423c-822d-cd06b60caabe	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d91179bf-48ce-423c-822d-cd06b60caabe	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d91179bf-48ce-423c-822d-cd06b60caabe	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d91179bf-48ce-423c-822d-cd06b60caabe	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d91179bf-48ce-423c-822d-cd06b60caabe	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19ee9e35-356b-4487-be7a-654fe88d8658	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19ee9e35-356b-4487-be7a-654fe88d8658	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19ee9e35-356b-4487-be7a-654fe88d8658	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19ee9e35-356b-4487-be7a-654fe88d8658	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19ee9e35-356b-4487-be7a-654fe88d8658	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19ee9e35-356b-4487-be7a-654fe88d8658	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00747110	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00747110	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00747110	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00747110	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00747110	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00747110	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	27/01/2012	https://clinicaltrials.gov/study/NCT01532648	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	27/01/2012	https://clinicaltrials.gov/study/NCT01532648	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	27/01/2012	https://clinicaltrials.gov/study/NCT01532648	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	27/01/2012	https://clinicaltrials.gov/study/NCT01532648	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	27/01/2012	https://clinicaltrials.gov/study/NCT01532648	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	27/01/2012	https://clinicaltrials.gov/study/NCT01532648	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e71e169-bc37-4a1f-bb7d-05bb55345742	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e71e169-bc37-4a1f-bb7d-05bb55345742	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e71e169-bc37-4a1f-bb7d-05bb55345742	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e71e169-bc37-4a1f-bb7d-05bb55345742	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e71e169-bc37-4a1f-bb7d-05bb55345742	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e71e169-bc37-4a1f-bb7d-05bb55345742	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00746447	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00746447	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00746447	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00746447	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00746447	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00746447	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01201122	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01201122	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01201122	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01201122	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01201122	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01201122	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02683733	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02683733	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02683733	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02683733	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02683733	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Unknown status	01/02/2016	https://clinicaltrials.gov/study/NCT02683733	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00073021	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00073021	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00073021	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00073021	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00073021	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00073021	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01320436	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01320436	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01320436	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01320436	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01320436	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	MESALAMINE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01320436	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	collagenous colitis	MESALAMINE	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00450086	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	collagenous colitis	MESALAMINE	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00450086	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	collagenous colitis	MESALAMINE	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00450086	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	collagenous colitis	MESALAMINE	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00450086	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	collagenous colitis	MESALAMINE	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00450086	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	collagenous colitis	MESALAMINE	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00450086	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	lymphocytic colitis	MESALAMINE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01209208	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	lymphocytic colitis	MESALAMINE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01209208	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	lymphocytic colitis	MESALAMINE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01209208	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	lymphocytic colitis	MESALAMINE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01209208	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	lymphocytic colitis	MESALAMINE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01209208	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	lymphocytic colitis	MESALAMINE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01209208	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	3	Terminated	30/11/2009	https://clinicaltrials.gov/study/NCT01016262	0.7	GoF	protect	The decision was taken solely for business/administrative reasons, no safety considerations entered into this. Ongoing randomized patients to complete.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	3	Terminated	30/11/2009	https://clinicaltrials.gov/study/NCT01016262	0.7	GoF	protect	The decision was taken solely for business/administrative reasons, no safety considerations entered into this. Ongoing randomized patients to complete.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	3	Terminated	30/11/2009	https://clinicaltrials.gov/study/NCT01016262	0.7	GoF	protect	The decision was taken solely for business/administrative reasons, no safety considerations entered into this. Ongoing randomized patients to complete.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	3	Terminated	30/11/2009	https://clinicaltrials.gov/study/NCT01016262	0.7	GoF	protect	The decision was taken solely for business/administrative reasons, no safety considerations entered into this. Ongoing randomized patients to complete.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	3	Terminated	30/11/2009	https://clinicaltrials.gov/study/NCT01016262	0.7	GoF	protect	The decision was taken solely for business/administrative reasons, no safety considerations entered into this. Ongoing randomized patients to complete.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	3	Terminated	30/11/2009	https://clinicaltrials.gov/study/NCT01016262	0.7	GoF	protect	The decision was taken solely for business/administrative reasons, no safety considerations entered into this. Ongoing randomized patients to complete.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89d91601-152b-4398-bebe-af1c023e9935	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89d91601-152b-4398-bebe-af1c023e9935	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89d91601-152b-4398-bebe-af1c023e9935	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89d91601-152b-4398-bebe-af1c023e9935	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89d91601-152b-4398-bebe-af1c023e9935	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89d91601-152b-4398-bebe-af1c023e9935	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef5c3f6-587e-48ea-a4b4-a7bf1bd749c6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef5c3f6-587e-48ea-a4b4-a7bf1bd749c6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef5c3f6-587e-48ea-a4b4-a7bf1bd749c6	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef5c3f6-587e-48ea-a4b4-a7bf1bd749c6	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef5c3f6-587e-48ea-a4b4-a7bf1bd749c6	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef5c3f6-587e-48ea-a4b4-a7bf1bd749c6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=357e0e6b-cfbd-454c-82d7-cfc460dc0d68	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=357e0e6b-cfbd-454c-82d7-cfc460dc0d68	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=357e0e6b-cfbd-454c-82d7-cfc460dc0d68	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=357e0e6b-cfbd-454c-82d7-cfc460dc0d68	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=357e0e6b-cfbd-454c-82d7-cfc460dc0d68	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=357e0e6b-cfbd-454c-82d7-cfc460dc0d68	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	3	Terminated	01/06/2010	https://clinicaltrials.gov/study/NCT01172444	0.7	GoF	protect	Enrollment difficulties
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	3	Terminated	01/06/2010	https://clinicaltrials.gov/study/NCT01172444	0.7	GoF	protect	Enrollment difficulties
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	3	Terminated	01/06/2010	https://clinicaltrials.gov/study/NCT01172444	0.7	GoF	protect	Enrollment difficulties
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	3	Terminated	01/06/2010	https://clinicaltrials.gov/study/NCT01172444	0.7	GoF	protect	Enrollment difficulties
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	3	Terminated	01/06/2010	https://clinicaltrials.gov/study/NCT01172444	0.7	GoF	protect	Enrollment difficulties
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	proctitis	MESALAMINE	targetBased	3	Terminated	01/06/2010	https://clinicaltrials.gov/study/NCT01172444	0.7	GoF	protect	Enrollment difficulties
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00300118	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00300118	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00300118	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00300118	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00300118	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00300118	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Terminated	01/04/2009	https://clinicaltrials.gov/study/NCT00862121	0.7	GoF	protect	Terminated due to poor recruitment
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Terminated	01/04/2009	https://clinicaltrials.gov/study/NCT00862121	0.7	GoF	protect	Terminated due to poor recruitment
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Terminated	01/04/2009	https://clinicaltrials.gov/study/NCT00862121	0.7	GoF	protect	Terminated due to poor recruitment
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Terminated	01/04/2009	https://clinicaltrials.gov/study/NCT00862121	0.7	GoF	protect	Terminated due to poor recruitment
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Terminated	01/04/2009	https://clinicaltrials.gov/study/NCT00862121	0.7	GoF	protect	Terminated due to poor recruitment
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Terminated	01/04/2009	https://clinicaltrials.gov/study/NCT00862121	0.7	GoF	protect	Terminated due to poor recruitment
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01514240	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01514240	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01514240	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01514240	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01514240	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01514240	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00167882	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00167882	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00167882	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00167882	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00167882	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00167882	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00245505	0.7	GoF	protect	Study terminated due to lack of eligible patients
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00245505	0.7	GoF	protect	Study terminated due to lack of eligible patients
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00245505	0.7	GoF	protect	Study terminated due to lack of eligible patients
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00245505	0.7	GoF	protect	Study terminated due to lack of eligible patients
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00245505	0.7	GoF	protect	Study terminated due to lack of eligible patients
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00245505	0.7	GoF	protect	Study terminated due to lack of eligible patients
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00946946	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00946946	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00946946	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00946946	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00946946	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00946946	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00976690	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00976690	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00976690	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00976690	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00976690	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00976690	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Active, not recruiting	20/11/2017	https://clinicaltrials.gov/study/NCT03261206	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Active, not recruiting	20/11/2017	https://clinicaltrials.gov/study/NCT03261206	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Active, not recruiting	20/11/2017	https://clinicaltrials.gov/study/NCT03261206	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Active, not recruiting	20/11/2017	https://clinicaltrials.gov/study/NCT03261206	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Active, not recruiting	20/11/2017	https://clinicaltrials.gov/study/NCT03261206	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Active, not recruiting	20/11/2017	https://clinicaltrials.gov/study/NCT03261206	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Terminated	01/02/2013	https://clinicaltrials.gov/study/NCT01696942	1	GoF	protect	Lack of accrual
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Terminated	01/02/2013	https://clinicaltrials.gov/study/NCT01696942	1	GoF	protect	Lack of accrual
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Terminated	01/02/2013	https://clinicaltrials.gov/study/NCT01696942	1	GoF	protect	Lack of accrual
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Terminated	01/02/2013	https://clinicaltrials.gov/study/NCT01696942	1	GoF	protect	Lack of accrual
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Terminated	01/02/2013	https://clinicaltrials.gov/study/NCT01696942	1	GoF	protect	Lack of accrual
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Crohn's disease	MESALAMINE	targetBased	4	Terminated	01/02/2013	https://clinicaltrials.gov/study/NCT01696942	1	GoF	protect	Lack of accrual
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	anaphylaxis	ALBUTEROL	targetBased	4	Completed	09/12/2019	https://clinicaltrials.gov/study/NCT04207840	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	seasonal allergic rhinitis	ALBUTEROL	targetBased	3	Completed	20/07/2015	https://clinicaltrials.gov/study/NCT02478398	0.7	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		inflammation	KETAMINE	targetBased	4	Unknown status	01/04/2011	https://clinicaltrials.gov/study/NCT01339065	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	multiple sclerosis	METHYLPHENIDATE	targetBased	3	Completed	04/10/2017	https://clinicaltrials.gov/study/NCT03185065	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	22q11.2 deletion syndrome	METHYLPHENIDATE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		multiple sclerosis	MEMANTINE	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00638027	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		multiple sclerosis	MEMANTINE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT01074619	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	relapsing-remitting multiple sclerosis	LOPERAMIDE	targetBased	4	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02217982	1	GoF	protect	Study did not meet required enrollment numbers
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	relapsing-remitting multiple sclerosis	LOPERAMIDE	targetBased	4	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02217982	1	GoF	protect	Study did not meet required enrollment numbers
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	immune system disease	POMALIDOMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AX06	1	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCITRIOL	targetBased	4	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02186665	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa4ab07-3d8e-4300-91f3-b1e17cba8691	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCITRIOL	targetBased	4	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00988637	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCITRIOL	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01205880	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCITRIOL	targetBased	4	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01766440	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCITRIOL	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01012713	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCITRIOL	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00658788	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCITRIOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=D05AX03	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1567da9-af74-4afd-9ac5-8b53ec5d7cbf	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCITRIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1567da9-af74-4afd-9ac5-8b53ec5d7cbf	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCITRIOL	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02125279	1	GoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	immune system disease	LENALIDOMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AX04	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	rheumatoid arthritis	BAZEDOXIFENE	targetBased	4	Completed	29/12/2015	https://clinicaltrials.gov/study/NCT02602704	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	rheumatoid arthritis	BAZEDOXIFENE	targetBased	4	Completed	29/12/2015	https://clinicaltrials.gov/study/NCT02602704	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	rheumatoid arthritis	BAZEDOXIFENE	targetBased	4	Completed	29/12/2015	https://clinicaltrials.gov/study/NCT02602704	1		protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Arthropathy	NALBUPHINE	targetBased	4	Completed	06/04/2022	https://clinicaltrials.gov/study/NCT05266027	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	allergic disease	NALBUPHINE	targetBased	4	Recruiting	05/09/2021	https://clinicaltrials.gov/study/NCT05073744	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	allergic disease	NALBUPHINE	targetBased	4	Recruiting	05/09/2021	https://clinicaltrials.gov/study/NCT05073744	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Arthropathy	NALBUPHINE	targetBased	4	Completed	06/04/2022	https://clinicaltrials.gov/study/NCT05266027	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Arthropathy	NALBUPHINE	targetBased	4	Completed	06/04/2022	https://clinicaltrials.gov/study/NCT05266027	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	allergic disease	NALBUPHINE	targetBased	4	Recruiting	05/09/2021	https://clinicaltrials.gov/study/NCT05073744	1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	graft versus host disease	IMATINIB	targetBased	3	Completed	29/06/2017	https://clinicaltrials.gov/study/NCT03112603	0.7	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	psoriasis	CAPSAICIN	targetBased	4	Terminated	01/06/2006	https://clinicaltrials.gov/study/NCT00697034	1		protect	Lack of qualified and willing volunteers.
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	allergic rhinitis	CAPSAICIN	targetBased	4	Unknown status	01/09/2008	https://clinicaltrials.gov/study/NCT00825656	1		protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	inflammatory bowel disease	CHOLECALCIFEROL	targetBased	3	Recruiting	21/09/2022	https://clinicaltrials.gov/study/NCT04991324	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	ulcerative colitis	CHOLECALCIFEROL	targetBased	3	Active, not recruiting	01/08/2017	https://clinicaltrials.gov/study/NCT03162432	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	relapsing-remitting multiple sclerosis	CHOLECALCIFEROL	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01490502	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Crohn's disease	CHOLECALCIFEROL	targetBased	3	Recruiting	07/02/2020	https://clinicaltrials.gov/study/NCT03999580	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Crohn's disease	CHOLECALCIFEROL	targetBased	3	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02186275	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Crohn's disease	CHOLECALCIFEROL	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01369667	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Crohn's disease	CHOLECALCIFEROL	targetBased	4	Withdrawn	01/05/2008	https://clinicaltrials.gov/study/NCT00672763	1	GoF	protect	Unable to recruit adequate trial participants
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Crohn's disease	CHOLECALCIFEROL	targetBased	3	Active, not recruiting	01/08/2017	https://clinicaltrials.gov/study/NCT03162432	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	inflammation	CHOLECALCIFEROL	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT02920502	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	seasonal allergic rhinitis	CHOLECALCIFEROL	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01103934	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	multiple sclerosis	CHOLECALCIFEROL	targetBased	4	Unknown status	01/03/2008	https://clinicaltrials.gov/study/NCT01339676	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	multiple sclerosis	CHOLECALCIFEROL	targetBased	4	Terminated	01/10/2010	https://clinicaltrials.gov/study/NCT01005095	0.5	GoF	protect	Interim analysis showed that the odds for proving primary hypothesis are low.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	multiple sclerosis	CHOLECALCIFEROL	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00785473	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	polymorphic light eruption	CHOLECALCIFEROL	targetBased	3	Terminated	01/04/2012	https://clinicaltrials.gov/study/NCT01595893	0.7	GoF	protect	Difficulties in recruiting the planned number of patients
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	immune system disease	FINGOLIMOD	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA27	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	immune system disease	FINGOLIMOD	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA27	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	immune system disease	FINGOLIMOD	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA27	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	13/09/2010	https://clinicaltrials.gov/study/NCT01201356	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e7daf4-ea90-5e47-e053-2a95a90ac1b7	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257358	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	26/07/2013	https://clinicaltrials.gov/study/NCT01892722	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT01621269	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01333501	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02048072	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	05/10/2021	https://clinicaltrials.gov/study/NCT04926818	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	29/04/2012	https://clinicaltrials.gov/study/NCT01585298	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	09/08/2012	https://clinicaltrials.gov/study/NCT01633112	0.7	GoF	protect	slow recruitment
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00340834	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00662649	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01578330	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00355134	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	3	Withdrawn	01/06/2014	https://clinicaltrials.gov/study/NCT01941004	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01216072	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4	Active, not recruiting	20/02/2021	https://clinicaltrials.gov/study/NCT04667949	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	29/09/2014	https://clinicaltrials.gov/study/NCT02232061	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01497262	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	4	Recruiting	12/10/2020	https://clinicaltrials.gov/study/NCT04480853	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01199861	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01127750	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	primary progressive multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01779934	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	primary progressive multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01779934	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	primary progressive multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	28/07/2008	https://clinicaltrials.gov/study/NCT00731692	0.7	GoF	protect	The extension study was terminated early after the results of the core study showed the study did not meet primary endpoint; confirmed disability progression
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	primary progressive multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	28/07/2008	https://clinicaltrials.gov/study/NCT00731692	0.7	GoF	protect	The extension study was terminated early after the results of the core study showed the study did not meet primary endpoint; confirmed disability progression
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Recruiting	12/10/2020	https://clinicaltrials.gov/study/NCT04480853	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Recruiting	12/10/2020	https://clinicaltrials.gov/study/NCT04480853	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	09/08/2012	https://clinicaltrials.gov/study/NCT01633112	0.7	GoF	protect	slow recruitment
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	09/08/2012	https://clinicaltrials.gov/study/NCT01633112	0.7	GoF	protect	slow recruitment
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257358	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257358	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	29/09/2014	https://clinicaltrials.gov/study/NCT02232061	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	29/09/2014	https://clinicaltrials.gov/study/NCT02232061	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT01621269	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT01621269	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02048072	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02048072	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00340834	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00340834	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e7daf4-ea90-5e47-e053-2a95a90ac1b7	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e7daf4-ea90-5e47-e053-2a95a90ac1b7	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01497262	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01497262	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01333501	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01333501	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00662649	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00662649	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Withdrawn	01/06/2014	https://clinicaltrials.gov/study/NCT01941004	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Withdrawn	01/06/2014	https://clinicaltrials.gov/study/NCT01941004	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01216072	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01216072	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01578330	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01578330	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	26/07/2013	https://clinicaltrials.gov/study/NCT01892722	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	26/07/2013	https://clinicaltrials.gov/study/NCT01892722	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01127750	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01127750	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00355134	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00355134	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01199861	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01199861	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	05/10/2021	https://clinicaltrials.gov/study/NCT04926818	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	05/10/2021	https://clinicaltrials.gov/study/NCT04926818	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Active, not recruiting	20/02/2021	https://clinicaltrials.gov/study/NCT04667949	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Active, not recruiting	20/02/2021	https://clinicaltrials.gov/study/NCT04667949	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	13/09/2010	https://clinicaltrials.gov/study/NCT01201356	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	13/09/2010	https://clinicaltrials.gov/study/NCT01201356	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	29/04/2012	https://clinicaltrials.gov/study/NCT01585298	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	29/04/2012	https://clinicaltrials.gov/study/NCT01585298	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	primary progressive multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	28/07/2008	https://clinicaltrials.gov/study/NCT00731692	0.7	GoF	protect	The extension study was terminated early after the results of the core study showed the study did not meet primary endpoint; confirmed disability progression
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	primary progressive multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01779934	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01420055	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Not yet recruiting	09/07/2024	https://clinicaltrials.gov/study/NCT06408259	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	20/08/2012	https://clinicaltrials.gov/study/NCT01705236	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00289978	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01310166	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	01/01/2013	https://clinicaltrials.gov/study/NCT01755871	1	GoF	protect	lack of recruitment
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Unknown status	01/03/2014	https://clinicaltrials.gov/study/NCT02325440	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01534182	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	01/09/2011	https://clinicaltrials.gov/study/NCT01499667	0.7	GoF	protect	Based on recent publications, determination of natalizumub washout period was no longer relevant.
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	24/12/2011	https://clinicaltrials.gov/study/NCT01498887	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	30/11/2014	https://clinicaltrials.gov/study/NCT02342704	1	GoF	protect	Business Decision
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	04/02/2022	https://clinicaltrials.gov/study/NCT05123703	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	30/04/2017	https://clinicaltrials.gov/study/NCT03345940	1	GoF	protect	termination of the study due to the slowness of the recruitment activity, according to the contract signed with the Sponsor
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	12/05/2016	https://clinicaltrials.gov/study/NCT02720107	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01317004	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	08/06/2012	https://clinicaltrials.gov/study/NCT01623596	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	31/03/2015	https://clinicaltrials.gov/study/NCT02373098	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01534182	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	01/09/2011	https://clinicaltrials.gov/study/NCT01499667	0.7	GoF	protect	Based on recent publications, determination of natalizumub washout period was no longer relevant.
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	12/05/2016	https://clinicaltrials.gov/study/NCT02720107	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	30/11/2014	https://clinicaltrials.gov/study/NCT02342704	1	GoF	protect	Business Decision
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00289978	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	31/03/2015	https://clinicaltrials.gov/study/NCT02373098	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01310166	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	20/08/2012	https://clinicaltrials.gov/study/NCT01705236	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01420055	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Not yet recruiting	09/07/2024	https://clinicaltrials.gov/study/NCT06408259	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	08/06/2012	https://clinicaltrials.gov/study/NCT01623596	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01317004	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	04/02/2022	https://clinicaltrials.gov/study/NCT05123703	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Unknown status	01/03/2014	https://clinicaltrials.gov/study/NCT02325440	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	30/04/2017	https://clinicaltrials.gov/study/NCT03345940	1	GoF	protect	termination of the study due to the slowness of the recruitment activity, according to the contract signed with the Sponsor
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	01/01/2013	https://clinicaltrials.gov/study/NCT01755871	1	GoF	protect	lack of recruitment
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	24/12/2011	https://clinicaltrials.gov/study/NCT01498887	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Unknown status	01/03/2014	https://clinicaltrials.gov/study/NCT02325440	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Unknown status	01/03/2014	https://clinicaltrials.gov/study/NCT02325440	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Not yet recruiting	09/07/2024	https://clinicaltrials.gov/study/NCT06408259	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Not yet recruiting	09/07/2024	https://clinicaltrials.gov/study/NCT06408259	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01317004	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01317004	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01534182	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01534182	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01420055	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01420055	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01310166	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01310166	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	30/04/2017	https://clinicaltrials.gov/study/NCT03345940	1	GoF	protect	termination of the study due to the slowness of the recruitment activity, according to the contract signed with the Sponsor
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	30/04/2017	https://clinicaltrials.gov/study/NCT03345940	1	GoF	protect	termination of the study due to the slowness of the recruitment activity, according to the contract signed with the Sponsor
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	12/05/2016	https://clinicaltrials.gov/study/NCT02720107	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	12/05/2016	https://clinicaltrials.gov/study/NCT02720107	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	24/12/2011	https://clinicaltrials.gov/study/NCT01498887	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	24/12/2011	https://clinicaltrials.gov/study/NCT01498887	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	04/02/2022	https://clinicaltrials.gov/study/NCT05123703	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	04/02/2022	https://clinicaltrials.gov/study/NCT05123703	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	08/06/2012	https://clinicaltrials.gov/study/NCT01623596	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	08/06/2012	https://clinicaltrials.gov/study/NCT01623596	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	01/09/2011	https://clinicaltrials.gov/study/NCT01499667	0.7	GoF	protect	Based on recent publications, determination of natalizumub washout period was no longer relevant.
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	01/09/2011	https://clinicaltrials.gov/study/NCT01499667	0.7	GoF	protect	Based on recent publications, determination of natalizumub washout period was no longer relevant.
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	01/01/2013	https://clinicaltrials.gov/study/NCT01755871	1	GoF	protect	lack of recruitment
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	01/01/2013	https://clinicaltrials.gov/study/NCT01755871	1	GoF	protect	lack of recruitment
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00289978	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00289978	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	30/11/2014	https://clinicaltrials.gov/study/NCT02342704	1	GoF	protect	Business Decision
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	30/11/2014	https://clinicaltrials.gov/study/NCT02342704	1	GoF	protect	Business Decision
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	20/08/2012	https://clinicaltrials.gov/study/NCT01705236	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	20/08/2012	https://clinicaltrials.gov/study/NCT01705236	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	31/03/2015	https://clinicaltrials.gov/study/NCT02373098	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	31/03/2015	https://clinicaltrials.gov/study/NCT02373098	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	30/11/2014	https://clinicaltrials.gov/study/NCT02342704	1	GoF	protect	Business Decision
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	30/11/2014	https://clinicaltrials.gov/study/NCT02342704	1	GoF	protect	Business Decision
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	24/12/2011	https://clinicaltrials.gov/study/NCT01498887	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	24/12/2011	https://clinicaltrials.gov/study/NCT01498887	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	31/03/2015	https://clinicaltrials.gov/study/NCT02373098	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	31/03/2015	https://clinicaltrials.gov/study/NCT02373098	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01420055	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01420055	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Not yet recruiting	09/07/2024	https://clinicaltrials.gov/study/NCT06408259	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Not yet recruiting	09/07/2024	https://clinicaltrials.gov/study/NCT06408259	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	01/09/2011	https://clinicaltrials.gov/study/NCT01499667	0.7	GoF	protect	Based on recent publications, determination of natalizumub washout period was no longer relevant.
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	01/09/2011	https://clinicaltrials.gov/study/NCT01499667	0.7	GoF	protect	Based on recent publications, determination of natalizumub washout period was no longer relevant.
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01317004	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01317004	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	01/01/2013	https://clinicaltrials.gov/study/NCT01755871	1	GoF	protect	lack of recruitment
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	01/01/2013	https://clinicaltrials.gov/study/NCT01755871	1	GoF	protect	lack of recruitment
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01534182	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01534182	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Unknown status	01/03/2014	https://clinicaltrials.gov/study/NCT02325440	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Unknown status	01/03/2014	https://clinicaltrials.gov/study/NCT02325440	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00289978	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00289978	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	12/05/2016	https://clinicaltrials.gov/study/NCT02720107	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	12/05/2016	https://clinicaltrials.gov/study/NCT02720107	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	30/04/2017	https://clinicaltrials.gov/study/NCT03345940	1	GoF	protect	termination of the study due to the slowness of the recruitment activity, according to the contract signed with the Sponsor
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Terminated	30/04/2017	https://clinicaltrials.gov/study/NCT03345940	1	GoF	protect	termination of the study due to the slowness of the recruitment activity, according to the contract signed with the Sponsor
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	20/08/2012	https://clinicaltrials.gov/study/NCT01705236	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	20/08/2012	https://clinicaltrials.gov/study/NCT01705236	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01310166	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01310166	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	08/06/2012	https://clinicaltrials.gov/study/NCT01623596	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	08/06/2012	https://clinicaltrials.gov/study/NCT01623596	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	04/02/2022	https://clinicaltrials.gov/study/NCT05123703	0.7	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	relapsing-remitting multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	04/02/2022	https://clinicaltrials.gov/study/NCT05123703	0.7	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	primary progressive multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	28/07/2008	https://clinicaltrials.gov/study/NCT00731692	0.7	GoF	protect	The extension study was terminated early after the results of the core study showed the study did not meet primary endpoint; confirmed disability progression
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	primary progressive multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01779934	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Recruiting	12/10/2020	https://clinicaltrials.gov/study/NCT04480853	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Recruiting	12/10/2020	https://clinicaltrials.gov/study/NCT04480853	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	09/08/2012	https://clinicaltrials.gov/study/NCT01633112	0.7	GoF	protect	slow recruitment
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	09/08/2012	https://clinicaltrials.gov/study/NCT01633112	0.7	GoF	protect	slow recruitment
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	05/10/2021	https://clinicaltrials.gov/study/NCT04926818	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	05/10/2021	https://clinicaltrials.gov/study/NCT04926818	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Withdrawn	01/06/2014	https://clinicaltrials.gov/study/NCT01941004	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Withdrawn	01/06/2014	https://clinicaltrials.gov/study/NCT01941004	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01216072	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01216072	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e7daf4-ea90-5e47-e053-2a95a90ac1b7	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e7daf4-ea90-5e47-e053-2a95a90ac1b7	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00662649	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00662649	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257358	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257358	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	26/07/2013	https://clinicaltrials.gov/study/NCT01892722	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	26/07/2013	https://clinicaltrials.gov/study/NCT01892722	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01199861	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01199861	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02048072	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02048072	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01127750	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01127750	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	29/04/2012	https://clinicaltrials.gov/study/NCT01585298	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	29/04/2012	https://clinicaltrials.gov/study/NCT01585298	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01497262	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01497262	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01578330	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01578330	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	13/09/2010	https://clinicaltrials.gov/study/NCT01201356	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	13/09/2010	https://clinicaltrials.gov/study/NCT01201356	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00340834	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00340834	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT01621269	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT01621269	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	29/09/2014	https://clinicaltrials.gov/study/NCT02232061	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	29/09/2014	https://clinicaltrials.gov/study/NCT02232061	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00355134	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00355134	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01333501	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01333501	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Active, not recruiting	20/02/2021	https://clinicaltrials.gov/study/NCT04667949	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD	targetBased	4	Active, not recruiting	20/02/2021	https://clinicaltrials.gov/study/NCT04667949	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	primary progressive multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	28/07/2008	https://clinicaltrials.gov/study/NCT00731692	0.7	GoF	protect	The extension study was terminated early after the results of the core study showed the study did not meet primary endpoint; confirmed disability progression
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	primary progressive multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	28/07/2008	https://clinicaltrials.gov/study/NCT00731692	0.7	GoF	protect	The extension study was terminated early after the results of the core study showed the study did not meet primary endpoint; confirmed disability progression
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	primary progressive multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01779934	0.7	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	primary progressive multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01779934	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00355134	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01199861	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257358	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01216072	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01497262	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	29/04/2012	https://clinicaltrials.gov/study/NCT01585298	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	29/09/2014	https://clinicaltrials.gov/study/NCT02232061	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02048072	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4	Withdrawn	01/06/2013	https://clinicaltrials.gov/study/NCT01621269	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	26/07/2013	https://clinicaltrials.gov/study/NCT01892722	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00662649	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00340834	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	3	Withdrawn	01/06/2014	https://clinicaltrials.gov/study/NCT01941004	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	13/09/2010	https://clinicaltrials.gov/study/NCT01201356	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4	Active, not recruiting	20/02/2021	https://clinicaltrials.gov/study/NCT04667949	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	3	Recruiting	05/10/2021	https://clinicaltrials.gov/study/NCT04926818	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e7daf4-ea90-5e47-e053-2a95a90ac1b7	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01127750	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	3	Terminated	09/08/2012	https://clinicaltrials.gov/study/NCT01633112	0.7	GoF	protect	slow recruitment
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4	Recruiting	12/10/2020	https://clinicaltrials.gov/study/NCT04480853	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01333501	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01578330	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	immune system disease	FINGOLIMOD	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA27	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	immune system disease	FINGOLIMOD	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA27	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	immune system disease	FINGOLIMOD	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA27	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	allergic rhinitis	SALMETEROL	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT01388595	1	GoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	multiple sclerosis	LEVETIRACETAM	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00423527	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Recruiting	22/03/2023	https://clinicaltrials.gov/study/NCT05919407	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Recruiting	22/03/2023	https://clinicaltrials.gov/study/NCT05919407	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209321s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209321s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f015fe60-3128-4a43-8c31-19fc6b5def3f	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f015fe60-3128-4a43-8c31-19fc6b5def3f	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2731310a-c060-4d3e-ba41-763d791f63a9	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2731310a-c060-4d3e-ba41-763d791f63a9	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f015fe60-3128-4a43-8c31-19fc6b5def3f	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f015fe60-3128-4a43-8c31-19fc6b5def3f	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2731310a-c060-4d3e-ba41-763d791f63a9	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2731310a-c060-4d3e-ba41-763d791f63a9	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209321s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209321s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Recruiting	22/03/2023	https://clinicaltrials.gov/study/NCT05919407	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Recruiting	22/03/2023	https://clinicaltrials.gov/study/NCT05919407	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Recruiting	22/03/2023	https://clinicaltrials.gov/study/NCT05919407	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Recruiting	22/03/2023	https://clinicaltrials.gov/study/NCT05919407	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Recruiting	22/03/2023	https://clinicaltrials.gov/study/NCT05919407	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2731310a-c060-4d3e-ba41-763d791f63a9	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2731310a-c060-4d3e-ba41-763d791f63a9	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2731310a-c060-4d3e-ba41-763d791f63a9	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209321s000lbl.pdf	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209321s000lbl.pdf	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209321s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f015fe60-3128-4a43-8c31-19fc6b5def3f	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f015fe60-3128-4a43-8c31-19fc6b5def3f	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f015fe60-3128-4a43-8c31-19fc6b5def3f	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	AMIFAMPRIDINE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00190268	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	multiple sclerosis	AMIFAMPRIDINE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00190268	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	AMIFAMPRIDINE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00190268	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	AMIFAMPRIDINE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00190268	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	multiple sclerosis	AMIFAMPRIDINE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00190268	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	AMIFAMPRIDINE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00190268	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	multiple sclerosis	AMIFAMPRIDINE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00190268	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	multiple sclerosis	MODAFINIL	targetBased	4	Completed	15/11/2018	https://clinicaltrials.gov/study/NCT03621761	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	multiple sclerosis	MODAFINIL	targetBased	3	Completed	04/10/2017	https://clinicaltrials.gov/study/NCT03185065	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	allergic disease	THIETHYLPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R06AD03	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	allergic disease	THIETHYLPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R06AD03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	allergic disease	THIETHYLPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R06AD03	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	allergic disease	THIETHYLPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R06AD03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	allergic disease	THIETHYLPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R06AD03	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	allergic disease	THIETHYLPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R06AD03	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	seasonal allergic rhinitis	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1239e824-aa60-4b7f-9910-81f96ebe6c70	1	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Crohn's disease	TOFACITINIB	targetBased	4	Recruiting	10/09/2019	https://clinicaltrials.gov/study/NCT03885713	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	immune system disease	TOFACITINIB	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L04AA29	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	TOFACITINIB	targetBased	4	Recruiting	10/09/2019	https://clinicaltrials.gov/study/NCT03885713	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	TOFACITINIB	targetBased	4	Recruiting	12/06/2024	https://clinicaltrials.gov/study/NCT06095128	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	TOFACITINIB	targetBased	3	Recruiting	12/08/2021	https://clinicaltrials.gov/study/NCT04624230	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	TOFACITINIB	targetBased	4	Terminated	16/11/2017	https://clinicaltrials.gov/study/NCT03281304	1	LoF	protect	The study terminated early due to business reasons, with the study already meeting its primary objective. The decision to terminate the trial was not based on any safety and/or efficacy concerns.
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	TOFACITINIB	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01458951	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	TOFACITINIB	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01465763	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	TOFACITINIB	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01470612	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	TOFACITINIB	targetBased	3	Completed	18/09/2020	https://clinicaltrials.gov/study/NCT04505410	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	TOFACITINIB	targetBased	3	Completed	20/07/2012	https://clinicaltrials.gov/study/NCT01458574	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	TOFACITINIB	targetBased	4	Not yet recruiting	01/01/2025	https://clinicaltrials.gov/study/NCT06465732	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriasis	TOFACITINIB	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01241591	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriasis	TOFACITINIB	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01186744	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriasis	TOFACITINIB	targetBased	3	Terminated	01/09/2010	https://clinicaltrials.gov/study/NCT01163253	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriasis	TOFACITINIB	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01519089	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriasis	TOFACITINIB	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01276639	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriasis	TOFACITINIB	targetBased	3	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT01815424	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriasis	TOFACITINIB	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01309737	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02566967	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00661661	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Completed	05/02/2007	https://clinicaltrials.gov/study/NCT00413699	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01039688	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00856544	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Terminated	05/06/2019	https://clinicaltrials.gov/study/NCT03970837	0.35	LoF	protect	Only Asia cohort is early terminated.Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4	Recruiting	31/05/2021	https://clinicaltrials.gov/study/NCT04927000	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT02831855	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4	Completed	16/02/2016	https://clinicaltrials.gov/study/NCT02321930	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00960440	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4	Not yet recruiting	31/03/2023	https://clinicaltrials.gov/study/NCT05803135	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Recruiting	10/12/2007	https://clinicaltrials.gov/study/NCT03414502	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4	Recruiting	04/11/2019	https://clinicaltrials.gov/study/NCT04485325	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf74ba2f-afc5-4baa-8594-979c889a5831	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00814307	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Recruiting	15/11/2023	https://clinicaltrials.gov/study/NCT06020144	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4	Completed	01/03/2020	https://clinicaltrials.gov/study/NCT04928066	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02187055	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4	Recruiting	20/05/2022	https://clinicaltrials.gov/study/NCT05606107	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4	Recruiting	01/05/2014	https://clinicaltrials.gov/study/NCT02157012	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4	Recruiting	01/03/2020	https://clinicaltrials.gov/study/NCT03976245	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	4	Completed	14/03/2014	https://clinicaltrials.gov/study/NCT02092467	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00847613	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Completed	16/05/2019	https://clinicaltrials.gov/study/NCT03980483	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00853385	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB	targetBased	3	Completed	18/11/2014	https://clinicaltrials.gov/study/NCT02281552	0.7	LoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	atopic eczema	TAPINAROF	targetBased	3	Completed	28/10/2021	https://clinicaltrials.gov/study/NCT05142774	0.7	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	atopic eczema	TAPINAROF	targetBased	3	Completed	01/09/2021	https://clinicaltrials.gov/study/NCT05014568	0.7	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	atopic eczema	TAPINAROF	targetBased	3	Recruiting	01/04/2022	https://clinicaltrials.gov/study/NCT05326672	0.7	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	atopic eczema	TAPINAROF	targetBased	3	Completed	23/09/2021	https://clinicaltrials.gov/study/NCT05032859	0.7	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	psoriasis	TAPINAROF	targetBased	4	Completed	12/01/2023	https://clinicaltrials.gov/study/NCT05680740	1	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	psoriasis	TAPINAROF	targetBased	3	Completed	21/05/2019	https://clinicaltrials.gov/study/NCT03956355	0.7	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	psoriasis	TAPINAROF	targetBased	3	Completed	13/08/2019	https://clinicaltrials.gov/study/NCT04053387	0.7	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	psoriasis	TAPINAROF	targetBased	3	Completed	06/06/2019	https://clinicaltrials.gov/study/NCT03983980	0.7	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	psoriasis	TAPINAROF	targetBased	4	Recruiting	01/06/2021	https://clinicaltrials.gov/study/NCT05064748	1	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	psoriasis	TAPINAROF	targetBased	4	Completed	13/03/2023	https://clinicaltrials.gov/study/NCT05789576	1	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	psoriasis	TAPINAROF	targetBased	4	Completed	27/02/2023	https://clinicaltrials.gov/study/NCT06103695	1	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	psoriasis	TAPINAROF	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf	1	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	psoriasis	TAPINAROF	targetBased	3	Recruiting	02/12/2021	https://clinicaltrials.gov/study/NCT05172726	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	graft versus host disease	HYDROXYCHLOROQUINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00031824	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	3	Recruiting	10/12/2007	https://clinicaltrials.gov/study/NCT03414502	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2d7be5a-98ee-4292-8715-46573dbe1c5b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7804f5d2-41a6-4523-a277-6967e984e88e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4	Completed	31/12/2015	https://clinicaltrials.gov/study/NCT02644499	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3279d780-0940-f462-9709-83c77f8ae241	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71a8ea7d-e71d-4b71-871e-b592dd7ad047	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6971241c-8323-456e-91a4-a404a9e100de	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	3	Terminated	01/09/2016	https://clinicaltrials.gov/study/NCT02930343	0.7	LoF	protect	Due to time constraints, the study was halted prematurely
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fd85527-b048-3f4a-e054-00144ff8d46c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02451748	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ed338b7-d0d8-4e8c-96b7-af6346ad3189	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4	Recruiting	22/12/2021	https://clinicaltrials.gov/study/NCT05626348	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d22f0a8-170b-4c3e-8c2e-a5cf64b9958b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01709578	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b82bbda6-64f2-4426-b4ec-254eeea895ae	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff0c9d83-6d86-4d22-939b-a838bffbcfd0	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed80a489-672a-406f-b623-ee78ec150bed	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01768572	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00764725	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1dd8d688-8dce-4b06-aeb1-3447caba1cba	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a99dbe0-2055-4513-b182-0416ceecd5f1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4	Not yet recruiting	01/03/2019	https://clinicaltrials.gov/study/NCT03813771	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c293257e-ecd1-4c41-994e-0fe15dee41d2	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=805a1acd-2e0d-48f1-af6b-0e5d8e06c228	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88bd448d-bac7-4839-816a-8b800d7705c4	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16ea7eee-51c9-4305-9808-358e3ace31bd	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6016af90-6311-4f35-bfc3-ce49c105ba4f	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1aa44bff-9a62-48b4-a520-98d7d524e3a9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	3	Completed	20/11/2013	https://clinicaltrials.gov/study/NCT01941095	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34496b43-05a2-45fb-a769-52b12e099341	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	3	Completed	27/03/2001	https://clinicaltrials.gov/study/NCT00579878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT02433184	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00422227	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5869e45-27fc-4f33-80db-4a509b8256c1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a047f49-ccb5-4cb6-b0d6-8abfa9c39f2e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4	Recruiting	30/03/2016	https://clinicaltrials.gov/study/NCT02714634	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=631ed616-f23c-43c9-b63b-f53707c077cb	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adf36d25-d86e-4d2d-b90c-e29f1394667d	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22d4d993-b86d-478e-ac6d-7bcd217e9906	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bd923b1-f9e9-484d-a713-1329654d7ca4	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35314d43-3dec-46dd-8975-56f257b2f408	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02057250	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02374021	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1959d645-6b82-4f4d-b1f2-af644dec7c8f	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00259610	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4	Completed	05/03/2018	https://clinicaltrials.gov/study/NCT03449758	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ce83016-a5fc-71cf-92df-b8194f6b525d	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4	Unknown status	03/02/2015	https://clinicaltrials.gov/study/NCT02466581	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a1c868-b92f-4386-b8f9-8719dd785954	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	antiphospholipid syndrome	HYDROXYCHLOROQUINE	targetBased	3	Not yet recruiting	15/08/2018	https://clinicaltrials.gov/study/NCT03540810	0.7	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	ERGOCALCIFEROL	targetBased	4	Unknown status	01/04/2019	https://clinicaltrials.gov/study/NCT03904680	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	rheumatoid arthritis	ERGOCALCIFEROL	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01400516	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	inflammatory bowel disease	ERGOCALCIFEROL	targetBased	3	Recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05624801	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Crohn's disease	ERGOCALCIFEROL	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01792388	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Crohn's disease	ERGOCALCIFEROL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02010762	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	atopic eczema	ERGOCALCIFEROL	targetBased	4	Suspended	16/10/2017	https://clinicaltrials.gov/study/NCT03257215	1	GoF	protect	Recruitment very slow \& funding difficult - exacerbated by COVID-19 pandemic
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	food allergy	ERGOCALCIFEROL	targetBased	4	Active, not recruiting	01/12/2014	https://clinicaltrials.gov/study/NCT02112734	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	multiple sclerosis	ERGOCALCIFEROL	targetBased	3	Completed	16/07/2013	https://clinicaltrials.gov/study/NCT01817166	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	multiple sclerosis	ERGOCALCIFEROL	targetBased	3	Unknown status	01/03/2013	https://clinicaltrials.gov/study/NCT01768039	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		multiple sclerosis	AMANTADINE HYDROCHLORIDE	targetBased	3	Completed	18/07/2018	https://clinicaltrials.gov/study/NCT03567057	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		multiple sclerosis	AMANTADINE HYDROCHLORIDE	targetBased	3	Completed	29/03/2018	https://clinicaltrials.gov/study/NCT03436199	0.7	LoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	graft versus host disease	PANOBINOSTAT	targetBased	4	Recruiting	05/03/2015	https://clinicaltrials.gov/study/NCT02386800	1	LoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	rheumatoid arthritis	TERIPARATIDE	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01400516	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed80a489-672a-406f-b623-ee78ec150bed	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34496b43-05a2-45fb-a769-52b12e099341	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b82bbda6-64f2-4426-b4ec-254eeea895ae	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16ea7eee-51c9-4305-9808-358e3ace31bd	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a047f49-ccb5-4cb6-b0d6-8abfa9c39f2e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fd85527-b048-3f4a-e054-00144ff8d46c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6016af90-6311-4f35-bfc3-ce49c105ba4f	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d22f0a8-170b-4c3e-8c2e-a5cf64b9958b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff0c9d83-6d86-4d22-939b-a838bffbcfd0	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7804f5d2-41a6-4523-a277-6967e984e88e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ce83016-a5fc-71cf-92df-b8194f6b525d	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a1c868-b92f-4386-b8f9-8719dd785954	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1959d645-6b82-4f4d-b1f2-af644dec7c8f	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00422227	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88bd448d-bac7-4839-816a-8b800d7705c4	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adf36d25-d86e-4d2d-b90c-e29f1394667d	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1dd8d688-8dce-4b06-aeb1-3447caba1cba	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71a8ea7d-e71d-4b71-871e-b592dd7ad047	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ed338b7-d0d8-4e8c-96b7-af6346ad3189	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c293257e-ecd1-4c41-994e-0fe15dee41d2	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=631ed616-f23c-43c9-b63b-f53707c077cb	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3279d780-0940-f462-9709-83c77f8ae241	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a99dbe0-2055-4513-b182-0416ceecd5f1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=805a1acd-2e0d-48f1-af6b-0e5d8e06c228	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5869e45-27fc-4f33-80db-4a509b8256c1	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2d7be5a-98ee-4292-8715-46573dbe1c5b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1aa44bff-9a62-48b4-a520-98d7d524e3a9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22d4d993-b86d-478e-ac6d-7bcd217e9906	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35314d43-3dec-46dd-8975-56f257b2f408	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bd923b1-f9e9-484d-a713-1329654d7ca4	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	rheumatoid arthritis	HYDROXYCHLOROQUINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6971241c-8323-456e-91a4-a404a9e100de	1	LoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e7daf4-ea90-5e47-e053-2a95a90ac1b7	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya	1	GoF	protect
Primary HTS Assay for S1P3 Antagonists	S1PR3	S1PR3	Sphingosine 1-phosphate receptor 3	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02048072	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e7daf4-ea90-5e47-e053-2a95a90ac1b7	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e7daf4-ea90-5e47-e053-2a95a90ac1b7	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02048072	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02048072	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya	1	GoF	protect
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	S1PR2	Sphingosine 1-phosphate receptor 2	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e7daf4-ea90-5e47-e053-2a95a90ac1b7	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e7daf4-ea90-5e47-e053-2a95a90ac1b7	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02048072	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02048072	1	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya	1	GoF	protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02048072	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	FINGOLIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e7daf4-ea90-5e47-e053-2a95a90ac1b7	1	GoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	MONOMETHYL FUMARATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210296s000lbl.pdf	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	allergic asthma	INDACATEROL	targetBased	3	Completed	10/09/2020	https://clinicaltrials.gov/study/NCT04259164	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neutropenia	PLINABULIN	targetBased	3	Active, not recruiting	23/10/2019	https://clinicaltrials.gov/study/NCT03294577	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	neutropenia	PLINABULIN	targetBased	3	Completed	29/05/2018	https://clinicaltrials.gov/study/NCT03102606	0.7	LoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	immune system disease	PONESIMOD	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA50	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	PONESIMOD	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/ponvory	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	PONESIMOD	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s000lbl.pdf	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	PONESIMOD	targetBased	3	Completed	04/06/2015	https://clinicaltrials.gov/study/NCT02425644	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	PONESIMOD	targetBased	3	Terminated	30/03/2017	https://clinicaltrials.gov/study/NCT02907177	0.7	GoF	protect	sponsor decision due to low recruitment
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	PONESIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5be69660-738c-4db7-b0d4-517aa873dc41	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	PONESIMOD	targetBased	3	Completed	05/07/2017	https://clinicaltrials.gov/study/NCT03232073	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Unknown status	16/01/2019	https://clinicaltrials.gov/study/NCT03827876	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf9ea848-3138-4f2d-9bc0-75b470a51d5c	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Recruiting	28/04/2020	https://clinicaltrials.gov/study/NCT04372277	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02733874	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=D05AX52	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00243464	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fff63bc7-6b92-4080-9a11-017124d95162	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=277d843a-0ea9-429d-813d-49ed72dafb64	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Withdrawn	15/05/2017	https://clinicaltrials.gov/study/NCT03079973	0.7	GoF	protect	Project development priorities changed.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01139580	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19b2ad8b-7486-409e-a7b3-3d75060544ff	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53c9942a-e861-493f-95c2-53446bc5f06d	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Completed	06/12/2022	https://clinicaltrials.gov/study/NCT06329258	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=875dd377-0dee-4798-b86c-88ccf9e34158	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Recruiting	24/06/2020	https://clinicaltrials.gov/study/NCT04555707	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00216879	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Completed	21/05/2018	https://clinicaltrials.gov/study/NCT03506477	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01195831	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe7cd92a-f066-4c4a-80c8-e3f929ad4181	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT02644954	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94d4f46a-f254-4fe2-b4bd-7a533d6324fe	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Completed	12/12/2017	https://clinicaltrials.gov/study/NCT03848871	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00216840	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00608777	1	GoF	protect	Withdrawal of marketing autorization of efalizumab by the EMEA.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	20/10/2017	https://clinicaltrials.gov/study/NCT03331523	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00279162	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00216827	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00689481	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=377eafda-737c-4ba2-9ec5-61209b8814ed	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c376bc8b-e046-4011-bb20-2cfda38d6cb8	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00574249	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fcca1d8-09b9-4484-8809-66778e181c06	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00688519	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef43ba2d-20ce-4415-b5c2-e486b836812e	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	03/10/2018	https://clinicaltrials.gov/study/NCT05174598	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Completed	01/11/2021	https://clinicaltrials.gov/study/NCT04227288	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Recruiting	24/01/2022	https://clinicaltrials.gov/study/NCT05249972	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00437619	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01745133	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00437255	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Completed	18/09/2017	https://clinicaltrials.gov/study/NCT03441789	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c02cc96-ecaa-467b-9acb-7cae57ec8e87	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03020199	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01422434	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=D05AX02	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac6739cd-df1b-45ce-b6fd-ba83815d0f68	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Completed	01/05/2017	https://clinicaltrials.gov/study/NCT03080545	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01761019	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21378c25-5622-8bf7-1a8c-b05940a846a0	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75541479-7a55-4e28-b693-04de56f73f7b	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=757c914f-dd8d-43cc-a973-212d591af4af	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92d53473-e33d-4490-9390-ec333dbf7676	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	3	Completed	15/02/2017	https://clinicaltrials.gov/study/NCT02899962	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01188928	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef43ba2d-20ce-4415-b5c2-e486b836812e	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT02004574	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fcca1d8-09b9-4484-8809-66778e181c06	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02132936	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=757c914f-dd8d-43cc-a973-212d591af4af	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1193df2-d53f-4342-bd9d-d9cba7c89709	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	3	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02668692	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	3	Completed	31/10/2018	https://clinicaltrials.gov/study/NCT03731091	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	3	Completed	24/01/2019	https://clinicaltrials.gov/study/NCT03806790	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	3	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02310646	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36c5c818-0d40-445e-a3c0-0f46723a25e2	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51f208d0-7b3f-44cc-8bed-92fa3d2e7bbe	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	3	Completed	12/12/2018	https://clinicaltrials.gov/study/NCT03802344	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1359f4b2-60c9-42c9-8b25-9ef955ffeae5	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00640822	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02533973	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c2ed55a-c7f2-42be-a194-bd498707ce3f	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4	Active, not recruiting	16/02/2022	https://clinicaltrials.gov/study/NCT05185258	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00216892	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00670241	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00248456	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00691002	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis vulgaris	CALCIPOTRIENE	targetBased	3	Completed	03/10/2017	https://clinicaltrials.gov/study/NCT03308799	0.7	GoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b52d057-2774-439f-962e-79a56d0579aa	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b52d057-2774-439f-962e-79a56d0579aa	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b52d057-2774-439f-962e-79a56d0579aa	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b52d057-2774-439f-962e-79a56d0579aa	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b52d057-2774-439f-962e-79a56d0579aa	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b52d057-2774-439f-962e-79a56d0579aa	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00486031	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00486031	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00486031	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00486031	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00486031	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00486031	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb60806f-ec1d-40c1-b9f4-cf091d68adb6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb60806f-ec1d-40c1-b9f4-cf091d68adb6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb60806f-ec1d-40c1-b9f4-cf091d68adb6	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb60806f-ec1d-40c1-b9f4-cf091d68adb6	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb60806f-ec1d-40c1-b9f4-cf091d68adb6	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb60806f-ec1d-40c1-b9f4-cf091d68adb6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0498308-14b2-4456-8e13-795f6fc8ea30	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0498308-14b2-4456-8e13-795f6fc8ea30	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0498308-14b2-4456-8e13-795f6fc8ea30	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0498308-14b2-4456-8e13-795f6fc8ea30	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0498308-14b2-4456-8e13-795f6fc8ea30	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0498308-14b2-4456-8e13-795f6fc8ea30	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcab4c61-9bfd-40ad-8389-65e077abd787	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcab4c61-9bfd-40ad-8389-65e077abd787	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcab4c61-9bfd-40ad-8389-65e077abd787	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcab4c61-9bfd-40ad-8389-65e077abd787	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcab4c61-9bfd-40ad-8389-65e077abd787	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcab4c61-9bfd-40ad-8389-65e077abd787	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f9f32c4-35c0-4357-a141-5eb77ac6500c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f9f32c4-35c0-4357-a141-5eb77ac6500c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f9f32c4-35c0-4357-a141-5eb77ac6500c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f9f32c4-35c0-4357-a141-5eb77ac6500c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f9f32c4-35c0-4357-a141-5eb77ac6500c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE DISODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f9f32c4-35c0-4357-a141-5eb77ac6500c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	BALSALAZIDE DISODIUM	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	neutropenia	LITHIUM CARBONATE	targetBased	3	Completed	01/08/2020	https://clinicaltrials.gov/study/NCT05221593	0.7	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	neutropenia	LITHIUM CARBONATE	targetBased	3	Completed	01/08/2020	https://clinicaltrials.gov/study/NCT05221593	0.7	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8512d0c6-db4e-4673-b3b4-28975c18413f	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd522a3-587e-44ab-9de3-a0fd079f2ffb	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd522a3-587e-44ab-9de3-a0fd079f2ffb	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd522a3-587e-44ab-9de3-a0fd079f2ffb	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd522a3-587e-44ab-9de3-a0fd079f2ffb	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd522a3-587e-44ab-9de3-a0fd079f2ffb	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd522a3-587e-44ab-9de3-a0fd079f2ffb	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	OLSALAZINE SODIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75a96561-6f52-4c11-a105-391fbbfe4827	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	appendicitis	GLYCOPYRROLATE	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	appendicitis	GLYCOPYRROLATE	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	appendicitis	GLYCOPYRROLATE	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	appendicitis	GLYCOPYRROLATE	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	appendicitis	GLYCOPYRROLATE	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	graft versus host disease	DECITABINE	targetBased	3	Not yet recruiting	01/07/2021	https://clinicaltrials.gov/study/NCT04945096	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute graft vs. host disease	DECITABINE	targetBased	3	Not yet recruiting	01/07/2023	https://clinicaltrials.gov/study/NCT05907499	0.7	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	acute graft vs. host disease	DECITABINE	targetBased	3	Not yet recruiting	01/08/2023	https://clinicaltrials.gov/study/NCT05669079	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Arthropathy	NALBUPHINE HYDROCHLORIDE	targetBased	4	Completed	06/04/2022	https://clinicaltrials.gov/study/NCT05266027	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	allergic disease	NALBUPHINE HYDROCHLORIDE	targetBased	4	Recruiting	05/09/2021	https://clinicaltrials.gov/study/NCT05073744	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	allergic disease	NALBUPHINE HYDROCHLORIDE	targetBased	4	Recruiting	05/09/2021	https://clinicaltrials.gov/study/NCT05073744	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Arthropathy	NALBUPHINE HYDROCHLORIDE	targetBased	4	Completed	06/04/2022	https://clinicaltrials.gov/study/NCT05266027	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Arthropathy	NALBUPHINE HYDROCHLORIDE	targetBased	4	Completed	06/04/2022	https://clinicaltrials.gov/study/NCT05266027	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	allergic disease	NALBUPHINE HYDROCHLORIDE	targetBased	4	Recruiting	05/09/2021	https://clinicaltrials.gov/study/NCT05073744	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	appendicitis	GLYCOPYRRONIUM	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	appendicitis	GLYCOPYRRONIUM	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	appendicitis	GLYCOPYRRONIUM	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	appendicitis	GLYCOPYRRONIUM	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	appendicitis	GLYCOPYRRONIUM	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	allergic asthma	GLYCOPYRRONIUM	targetBased	3	Completed	10/09/2020	https://clinicaltrials.gov/study/NCT04259164	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	allergic asthma	GLYCOPYRRONIUM	targetBased	3	Completed	10/09/2020	https://clinicaltrials.gov/study/NCT04259164	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	allergic asthma	GLYCOPYRRONIUM	targetBased	3	Completed	10/09/2020	https://clinicaltrials.gov/study/NCT04259164	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	appendicitis	GLYCOPYRRONIUM	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	appendicitis	GLYCOPYRRONIUM	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	appendicitis	GLYCOPYRRONIUM	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	appendicitis	GLYCOPYRRONIUM	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	appendicitis	GLYCOPYRRONIUM	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	appendicitis	GLYCOPYRRONIUM	targetBased	4	Recruiting	19/07/2023	https://clinicaltrials.gov/study/NCT05256901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	allergic asthma	GLYCOPYRRONIUM	targetBased	3	Completed	10/09/2020	https://clinicaltrials.gov/study/NCT04259164	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	allergic asthma	GLYCOPYRRONIUM	targetBased	3	Completed	10/09/2020	https://clinicaltrials.gov/study/NCT04259164	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	allergic asthma	GLYCOPYRRONIUM	targetBased	3	Completed	10/09/2020	https://clinicaltrials.gov/study/NCT04259164	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic asthma	GLYCOPYRRONIUM	targetBased	3	Completed	10/09/2020	https://clinicaltrials.gov/study/NCT04259164	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	allergic asthma	GLYCOPYRRONIUM	targetBased	3	Completed	10/09/2020	https://clinicaltrials.gov/study/NCT04259164	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	allergic asthma	GLYCOPYRRONIUM	targetBased	3	Completed	10/09/2020	https://clinicaltrials.gov/study/NCT04259164	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic asthma	GLYCOPYRRONIUM	targetBased	3	Completed	10/09/2020	https://clinicaltrials.gov/study/NCT04259164	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic asthma	GLYCOPYRRONIUM	targetBased	3	Completed	10/09/2020	https://clinicaltrials.gov/study/NCT04259164	0.7	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0498308-14b2-4456-8e13-795f6fc8ea30	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0498308-14b2-4456-8e13-795f6fc8ea30	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0498308-14b2-4456-8e13-795f6fc8ea30	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0498308-14b2-4456-8e13-795f6fc8ea30	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0498308-14b2-4456-8e13-795f6fc8ea30	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0498308-14b2-4456-8e13-795f6fc8ea30	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b52d057-2774-439f-962e-79a56d0579aa	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b52d057-2774-439f-962e-79a56d0579aa	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b52d057-2774-439f-962e-79a56d0579aa	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b52d057-2774-439f-962e-79a56d0579aa	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b52d057-2774-439f-962e-79a56d0579aa	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b52d057-2774-439f-962e-79a56d0579aa	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f12ffa32-d14b-e9d9-e957-2ef08b64e8b4	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509b83b6-cde6-393b-8560-557793b6a529	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f9f32c4-35c0-4357-a141-5eb77ac6500c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f9f32c4-35c0-4357-a141-5eb77ac6500c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f9f32c4-35c0-4357-a141-5eb77ac6500c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f9f32c4-35c0-4357-a141-5eb77ac6500c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f9f32c4-35c0-4357-a141-5eb77ac6500c	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f9f32c4-35c0-4357-a141-5eb77ac6500c	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00486031	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00486031	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00486031	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00486031	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00486031	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00486031	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22f41e83-b9fb-4c9e-8cc3-f457034191a8	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb60806f-ec1d-40c1-b9f4-cf091d68adb6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb60806f-ec1d-40c1-b9f4-cf091d68adb6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb60806f-ec1d-40c1-b9f4-cf091d68adb6	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb60806f-ec1d-40c1-b9f4-cf091d68adb6	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb60806f-ec1d-40c1-b9f4-cf091d68adb6	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb60806f-ec1d-40c1-b9f4-cf091d68adb6	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcab4c61-9bfd-40ad-8389-65e077abd787	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcab4c61-9bfd-40ad-8389-65e077abd787	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcab4c61-9bfd-40ad-8389-65e077abd787	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcab4c61-9bfd-40ad-8389-65e077abd787	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcab4c61-9bfd-40ad-8389-65e077abd787	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcab4c61-9bfd-40ad-8389-65e077abd787	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc5146c6-448b-44c9-bb06-8bdfe484f2f1	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ulcerative colitis	BALSALAZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3934dfa6-f2f7-4bdc-94fa-6c17224da61d	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	BALSALAZIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	BALSALAZIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	BALSALAZIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	BALSALAZIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	BALSALAZIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	inflammatory bowel disease	BALSALAZIDE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00408174	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	22q11.2 deletion syndrome	TERIPARATIDE ACETATE	targetBased	3	Terminated	30/10/2006	https://clinicaltrials.gov/study/NCT00395538	0.7	GoF	protect	Pharmacy temporarily suspended by FDA
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	immune system disease	EFALIZUMAB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA21	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	4	Unknown status	01/09/2008	https://clinicaltrials.gov/study/NCT00707070	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	4	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00739882	1	LoF	protect	The study was terminated after the European Medicines Agency recommended to suspend the marketing authorisation of Raptiva in the European Union
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00338143	0.7	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00256139	0.7	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	4	Completed	30/03/2006	https://clinicaltrials.gov/study/NCT00312026	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00109317	0.7	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00096603	0.7	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	4	Completed	27/10/2004	https://clinicaltrials.gov/study/NCT00287118	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00442650	0.7	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	4	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00697593	1	LoF	protect	The study was terminated after the European Medicines Agency recommended to suspend the marketing authorisation of Raptiva in the European Union
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00302445	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	4	Terminated	01/09/2008	https://clinicaltrials.gov/study/NCT00972543	1	LoF	protect	The study was terminated after the European Medicines Evaluation Agency recommended to suspend the marketing authorisation of Raptiva in the European Union
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	3	Completed	04/08/2003	https://clinicaltrials.gov/study/NCT00115076	0.7	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00669214	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	4	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00096980	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/raptiva	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00109252	0.7	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00336973	1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	psoriasis	EFALIZUMAB	targetBased	4	Completed	13/12/2004	https://clinicaltrials.gov/study/NCT00249808	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	multiple sclerosis	NATALIZUMAB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	multiple sclerosis	NATALIZUMAB	targetBased	4	Terminated	30/09/2014	https://clinicaltrials.gov/study/NCT02241785	1	LoF	protect	Business Decision
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	multiple sclerosis	NATALIZUMAB	targetBased	4	Completed	03/11/2016	https://clinicaltrials.gov/study/NCT03516526	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	multiple sclerosis	NATALIZUMAB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	multiple sclerosis	NATALIZUMAB	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00744679	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	multiple sclerosis	NATALIZUMAB	targetBased	4	Terminated	16/09/2022	https://clinicaltrials.gov/study/NCT05177718	1	LoF	protect	Sponsor declined further support
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	multiple sclerosis	NATALIZUMAB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125104s950lbl.pdf	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	multiple sclerosis	NATALIZUMAB	targetBased	4	Recruiting	12/06/2019	https://clinicaltrials.gov/study/NCT02769689	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	multiple sclerosis	NATALIZUMAB	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00276172	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	multiple sclerosis	NATALIZUMAB	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00536120	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	multiple sclerosis	NATALIZUMAB	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT03046251	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	multiple sclerosis	NATALIZUMAB	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02775110	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01144052	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	3	Terminated	01/03/2006	https://clinicaltrials.gov/study/NCT00297232	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	4	Terminated	30/11/2014	https://clinicaltrials.gov/study/NCT02342704	1	LoF	protect	Business Decision
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	4	Withdrawn	01/11/2008	https://clinicaltrials.gov/study/NCT00771043	1	LoF	protect	Sponsor decision to withdraw study at this time.
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	3	Completed	27/11/2018	https://clinicaltrials.gov/study/NCT03689972	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00871780	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	3	Terminated	26/04/2022	https://clinicaltrials.gov/study/NCT05265728	0.7	LoF	protect	Due to sponsor decision, not for efficacy or safety reasons.
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01591551	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	4	Enrolling by invitation	03/02/2020	https://clinicaltrials.gov/study/NCT04225312	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00027300	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00030966	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	3	Terminated	01/03/2010	https://clinicaltrials.gov/study/NCT01058005	0.7	LoF	protect	Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study.
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00306592	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	4	Unknown status	01/03/2014	https://clinicaltrials.gov/study/NCT02325440	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	relapsing-remitting multiple sclerosis	NATALIZUMAB	targetBased	4	Terminated	23/01/2023	https://clinicaltrials.gov/study/NCT05532163	1	LoF	protect	Sponsor's decision
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	immune system disease	NATALIZUMAB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA23	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	inflammation	NATALIZUMAB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	secondary progressive multiple sclerosis	NATALIZUMAB	targetBased	3	Terminated	13/09/2011	https://clinicaltrials.gov/study/NCT01416181	0.35	LoF	protect	The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	NATALIZUMAB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125104s950lbl.pdf	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	NATALIZUMAB	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00032799	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	NATALIZUMAB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	NATALIZUMAB	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00078611	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	NATALIZUMAB	targetBased	4	Withdrawn	01/12/2008	https://clinicaltrials.gov/study/NCT00801125	1	LoF	protect	Study sponsor decided to withdraw the current study prior to enrollment of first participant.
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	NATALIZUMAB	targetBased	4	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00280956	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	NATALIZUMAB	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT00032786	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	immune system disease	RILONACEPT	pathwayBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AC04	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Familial cold urticaria	RILONACEPT	pathwayBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00288704	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Familial cold urticaria	RILONACEPT	pathwayBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=282f4099-e848-432a-bac1-e041c192a5ba	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	systemic inflammatory response syndrome	CANAKINUMAB	pathwayBased	3	Completed	30/04/2020	https://clinicaltrials.gov/study/NCT04362813	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	immune system disease	CANAKINUMAB	pathwayBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AC08	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rheumatoid arthritis	TRAMADOL	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00246168	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rheumatoid arthritis	TRAMADOL	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00246168	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	anaphylaxis	ALBUTEROL SULFATE	targetBased	4	Completed	09/12/2019	https://clinicaltrials.gov/study/NCT04207840	1	GoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4	Withdrawn	01/07/2017	https://clinicaltrials.gov/study/NCT03237260	1	LoF	protect	No patient accrual
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02743806	1	LoF	protect	Early Completed - Alternative Source of Drug Available
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	3	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00783718	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	3	Active, not recruiting	15/04/2016	https://clinicaltrials.gov/study/NCT02620046	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	3	Completed	04/02/2014	https://clinicaltrials.gov/study/NCT02039505	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	3	Terminated	18/05/2017	https://clinicaltrials.gov/study/NCT02954159	0.7	LoF	protect	insufficient enrollment
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	3	Recruiting	18/04/2022	https://clinicaltrials.gov/study/NCT04779307	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	3	Completed	29/06/2015	https://clinicaltrials.gov/study/NCT02497469	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	3	Withdrawn	20/04/2021	https://clinicaltrials.gov/study/NCT04469062	0.7	LoF	protect	The trial was terminated secondary to a business decision, the original scientific question rendered moot by the external scientific community.
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4	Recruiting	01/01/2021	https://clinicaltrials.gov/study/NCT05481619	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	3	Completed	22/05/2009	https://clinicaltrials.gov/study/NCT00790933	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4	Recruiting	15/01/2022	https://clinicaltrials.gov/study/NCT05205603	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4	Recruiting	01/07/2019	https://clinicaltrials.gov/study/NCT04006080	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4	Withdrawn	01/11/2016	https://clinicaltrials.gov/study/NCT02760615	1	LoF	protect	No enrollment
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4	Recruiting	12/06/2024	https://clinicaltrials.gov/study/NCT06095128	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4	Completed	29/03/2017	https://clinicaltrials.gov/study/NCT03029143	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4	Recruiting	04/01/2019	https://clinicaltrials.gov/study/NCT03679546	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4	Completed	29/11/2017	https://clinicaltrials.gov/study/NCT02559713	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02646657	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	3	Completed	18/12/2015	https://clinicaltrials.gov/study/NCT02611830	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	3	Recruiting	03/08/2017	https://clinicaltrials.gov/study/NCT03221036	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	ulcerative colitis	VEDOLIZUMAB	targetBased	4	Recruiting	10/09/2019	https://clinicaltrials.gov/study/NCT03885713	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	immune system disease	VEDOLIZUMAB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA33	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02743806	1	LoF	protect	Early Completed - Alternative Source of Drug Available
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01224171	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00783692	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Active, not recruiting	08/06/2018	https://clinicaltrials.gov/study/NCT03142321	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02646683	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	3	Recruiting	16/06/2023	https://clinicaltrials.gov/study/NCT05837897	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Withdrawn	01/09/2016	https://clinicaltrials.gov/study/NCT02820493	1	LoF	protect	Internal problems
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Not yet recruiting	26/02/2024	https://clinicaltrials.gov/study/NCT06257706	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Terminated	01/04/2016	https://clinicaltrials.gov/study/NCT02324699	1	LoF	protect	Difficult recruitment
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Recruiting	10/09/2019	https://clinicaltrials.gov/study/NCT03885713	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	3	Active, not recruiting	15/04/2016	https://clinicaltrials.gov/study/NCT02620046	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	3	Completed	28/01/2014	https://clinicaltrials.gov/study/NCT02038920	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Completed	29/11/2017	https://clinicaltrials.gov/study/NCT02559713	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Recruiting	18/04/2024	https://clinicaltrials.gov/study/NCT06045754	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Terminated	01/07/2016	https://clinicaltrials.gov/study/NCT02768532	1	LoF	protect	low inclusion rates
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Withdrawn	01/11/2016	https://clinicaltrials.gov/study/NCT02760615	1	LoF	protect	No enrollment
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Completed	10/08/2016	https://clinicaltrials.gov/study/NCT02630966	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Completed	18/04/2017	https://clinicaltrials.gov/study/NCT02764762	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Recruiting	25/10/2023	https://clinicaltrials.gov/study/NCT05928039	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	3	Completed	04/01/2016	https://clinicaltrials.gov/study/NCT02611817	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	3	Completed	03/08/2017	https://clinicaltrials.gov/study/NCT03234907	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	3	Completed	22/05/2009	https://clinicaltrials.gov/study/NCT00790933	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06180382	1	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	3	Not yet recruiting	22/07/2024	https://clinicaltrials.gov/study/NCT06227910	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	3	Recruiting	30/04/2022	https://clinicaltrials.gov/study/NCT04779320	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	Crohn's disease	VEDOLIZUMAB	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02425111	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	acute graft vs. host disease	RUXOLITINIB	targetBased	3	Completed	10/03/2017	https://clinicaltrials.gov/study/NCT02913261	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	acute graft vs. host disease	RUXOLITINIB	targetBased	3	Terminated	16/06/2022	https://clinicaltrials.gov/study/NCT04934670	0.7	LoF	protect	The study met the protocol defined stopping boundary for Day 60 mortality when comparing mortality between the T-Guard and ruxolitinib arms
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	acute graft vs. host disease	RUXOLITINIB	targetBased	4	Recruiting	30/06/2024	https://clinicaltrials.gov/study/NCT06462469	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	macrophage activation syndrome	RUXOLITINIB	targetBased	3	Not yet recruiting	01/06/2022	https://clinicaltrials.gov/study/NCT05137496	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	RUXOLITINIB	targetBased	3	Active, not recruiting	01/09/2022	https://clinicaltrials.gov/study/NCT05456529	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	RUXOLITINIB	targetBased	3	Completed	20/12/2018	https://clinicaltrials.gov/study/NCT03745651	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	RUXOLITINIB	targetBased	3	Recruiting	26/04/2024	https://clinicaltrials.gov/study/NCT06238817	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	RUXOLITINIB	targetBased	4	Recruiting	16/03/2023	https://clinicaltrials.gov/study/NCT05696392	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	RUXOLITINIB	targetBased	3	Completed	19/07/2021	https://clinicaltrials.gov/study/NCT04921969	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	RUXOLITINIB	targetBased	3	Completed	20/12/2018	https://clinicaltrials.gov/study/NCT03745638	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	graft versus host disease	RUXOLITINIB	targetBased	4	Recruiting	08/04/2021	https://clinicaltrials.gov/study/NCT04838704	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	graft versus host disease	RUXOLITINIB	targetBased	4	Not yet recruiting	15/04/2024	https://clinicaltrials.gov/study/NCT06364319	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	graft versus host disease	RUXOLITINIB	targetBased	4	Recruiting	05/03/2015	https://clinicaltrials.gov/study/NCT02386800	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	graft versus host disease	RUXOLITINIB	targetBased	3	Completed	01/01/2019	https://clinicaltrials.gov/study/NCT05663827	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	graft versus host disease	RUXOLITINIB	targetBased	3	Completed	29/06/2017	https://clinicaltrials.gov/study/NCT03112603	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	graft versus host disease	RUXOLITINIB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	hemophagocytic syndrome	RUXOLITINIB	targetBased	3	Recruiting	01/07/2019	https://clinicaltrials.gov/study/NCT04120090	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Vitiligo	RUXOLITINIB	targetBased	3	Completed	20/09/2019	https://clinicaltrials.gov/study/NCT04052425	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Vitiligo	RUXOLITINIB	targetBased	3	Completed	03/10/2019	https://clinicaltrials.gov/study/NCT04057573	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Vitiligo	RUXOLITINIB	targetBased	3	Completed	24/09/2020	https://clinicaltrials.gov/study/NCT04530344	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	graft versus host disease	RUXOLITINIB PHOSPHATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	immune system disease	BELUMOSUDIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA48	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	graft versus host disease	BELUMOSUDIL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214783s000lbl.pdf	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	chronic graft versus host disease	BELUMOSUDIL	targetBased	3	Recruiting	23/01/2024	https://clinicaltrials.gov/study/NCT06143891	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf74ba2f-afc5-4baa-8594-979c889a5831	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB CITRATE	targetBased	4	Recruiting	01/05/2014	https://clinicaltrials.gov/study/NCT02157012	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	TOFACITINIB CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	immune system disease	BARICITINIB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA37	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	BARICITINIB	targetBased	3	Completed	15/05/2018	https://clinicaltrials.gov/study/NCT03428100	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	BARICITINIB	targetBased	3	Completed	16/11/2018	https://clinicaltrials.gov/study/NCT03733301	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	BARICITINIB	targetBased	3	Completed	28/03/2018	https://clinicaltrials.gov/study/NCT03334435	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	BARICITINIB	targetBased	3	Terminated	27/06/2018	https://clinicaltrials.gov/study/NCT03559270	0.7	LoF	protect	Terminated due to lack of alignment during regulatory negotiations.
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	BARICITINIB	targetBased	3	Active, not recruiting	24/05/2019	https://clinicaltrials.gov/study/NCT03952559	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	BARICITINIB	targetBased	3	Completed	23/11/2017	https://clinicaltrials.gov/study/NCT03334396	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	BARICITINIB	targetBased	3	Completed	20/02/2018	https://clinicaltrials.gov/study/NCT03435081	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	BARICITINIB	targetBased	3	Completed	27/11/2017	https://clinicaltrials.gov/study/NCT03334422	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	3	Active, not recruiting	11/09/2018	https://clinicaltrials.gov/study/NCT03701789	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	4	Recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT05955066	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01721044	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	4	Active, not recruiting	25/04/2019	https://clinicaltrials.gov/study/NCT03915964	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	3	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02265705	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01721057	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	4	Recruiting	01/04/2023	https://clinicaltrials.gov/study/NCT05827497	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	4	Recruiting	14/02/2020	https://clinicaltrials.gov/study/NCT04086745	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	3	Recruiting	10/12/2007	https://clinicaltrials.gov/study/NCT03414502	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	3	Recruiting	15/07/2021	https://clinicaltrials.gov/study/NCT04870203	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	3	Completed	27/06/2013	https://clinicaltrials.gov/study/NCT01885078	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	4	Terminated	27/06/2022	https://clinicaltrials.gov/study/NCT05238896	1	LoF	protect	Difficulties of inclusion in the study following expiry of the experimental treatment. The time required to supply the study treatment is too long to obtain conclusive results at the end of the study.
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	4	Completed	01/10/2022	https://clinicaltrials.gov/study/NCT05660655	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01711359	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	BARICITINIB	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01710358	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Active, not recruiting	09/06/2023	https://clinicaltrials.gov/study/NCT05658484	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Recruiting	23/07/2021	https://clinicaltrials.gov/study/NCT04788615	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Completed	12/03/2015	https://clinicaltrials.gov/study/NCT02410278	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a70cedb-d909-4d2a-8ab8-07d50a4609a4	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Terminated	01/04/2015	https://clinicaltrials.gov/study/NCT02428231	0.7	LoF	protect	Sponsor decision
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01873417	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Unknown status	01/02/2015	https://clinicaltrials.gov/study/NCT03092544	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Completed	19/03/2016	https://clinicaltrials.gov/study/NCT02739542	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Terminated	28/02/2015	https://clinicaltrials.gov/study/NCT02343159	1	LoF	protect	Sponsor Decision
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Completed	31/10/2013	https://clinicaltrials.gov/study/NCT01930708	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02683863	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Completed	11/08/2015	https://clinicaltrials.gov/study/NCT02525874	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	chronic progressive multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Terminated	01/05/2015	https://clinicaltrials.gov/study/NCT02430532	0.7	LoF	protect	Sponsor Decision
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	psoriasis	DIMETHYL FUMARATE	targetBased	4	Completed	04/09/2019	https://clinicaltrials.gov/study/NCT04263610	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	psoriasis	DIMETHYL FUMARATE	targetBased	3	Withdrawn	01/06/2016	https://clinicaltrials.gov/study/NCT01815723	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	psoriasis	DIMETHYL FUMARATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01726933	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Terminated	30/04/2017	https://clinicaltrials.gov/study/NCT03345940	1	LoF	protect	termination of the study due to the slowness of the recruitment activity, according to the contract signed with the Sponsor
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Withdrawn	01/04/2016	https://clinicaltrials.gov/study/NCT02675413	1	LoF	protect	Principal Investigator decided to withdraw.
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02090413	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Terminated	23/05/2017	https://clinicaltrials.gov/study/NCT02901106	1	LoF	protect	Another surveillance protocol was initiated by the OFSEP (OFSEP cohort) which allows to follow all the patients, whatever their treatment.
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Withdrawn	01/05/2016	https://clinicaltrials.gov/study/NCT02428218	0.7	LoF	protect	Feasibility
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02125604	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Completed	06/05/2015	https://clinicaltrials.gov/study/NCT02461069	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02746744	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Completed	03/02/2009	https://clinicaltrials.gov/study/NCT00835770	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Active, not recruiting	28/08/2014	https://clinicaltrials.gov/study/NCT02283853	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Completed	31/10/2013	https://clinicaltrials.gov/study/NCT01930708	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Completed	30/04/2014	https://clinicaltrials.gov/study/NCT02579681	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Completed	06/11/2015	https://clinicaltrials.gov/study/NCT02471560	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Withdrawn	01/06/2015	https://clinicaltrials.gov/study/NCT02090348	1	LoF	protect	The study was withdrawn for business reasons. The decision to stop the TECNERGY study was not a result of any safety or efficacy concerns.
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-neuraxpharm	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Terminated	19/03/2019	https://clinicaltrials.gov/study/NCT03870763	0.7	LoF	protect	Decision to stop the trial was based on long-term difficulties in fulfilling our enrolment commitments and changes in paediatric MS landscape which no longer support placebo-controlled trials.Decision to stop study was not based on safety concerns.
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03093324	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Completed	22/02/2016	https://clinicaltrials.gov/study/NCT02555215	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00451451	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Completed	11/08/2015	https://clinicaltrials.gov/study/NCT02525874	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Completed	28/03/2013	https://clinicaltrials.gov/study/NCT01838668	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00420212	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIMETHYL FUMARATE	targetBased	4	Withdrawn	01/07/2015	https://clinicaltrials.gov/study/NCT02472938	1	LoF	protect	Sponsor Decision
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	immune system disease	DIMETHYL FUMARATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AX07	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	seasonal allergic rhinitis	EPHEDRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1239e824-aa60-4b7f-9910-81f96ebe6c70	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	seasonal allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	allergic rhinitis	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	chronic progressive multiple sclerosis	SIPONIMOD	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	immune system disease	SIPONIMOD	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA42	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	SIPONIMOD	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	SIPONIMOD	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/mayzent	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	SIPONIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44492772-5aed-4627-bd85-e8e89f308bb3	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	SIPONIMOD	targetBased	3	Recruiting	05/10/2021	https://clinicaltrials.gov/study/NCT04926818	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	SIPONIMOD	targetBased	3	Completed	14/02/2019	https://clinicaltrials.gov/study/NCT03623243	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	SIPONIMOD	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	secondary progressive multiple sclerosis	SIPONIMOD	targetBased	3	Completed	20/12/2012	https://clinicaltrials.gov/study/NCT01665144	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	secondary progressive multiple sclerosis	SIPONIMOD	targetBased	4	Completed	19/04/2021	https://clinicaltrials.gov/study/NCT04792567	1	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	immune system disease	PEFICITINIB	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L04AA49	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	PEFICITINIB	targetBased	3	Completed	13/06/2012	https://clinicaltrials.gov/study/NCT01638013	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	PEFICITINIB	targetBased	3	Completed	25/07/2014	https://clinicaltrials.gov/study/NCT02305849	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	PEFICITINIB	targetBased	3	Completed	08/08/2014	https://clinicaltrials.gov/study/NCT02308163	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	PEFICITINIB	targetBased	3	Completed	27/09/2018	https://clinicaltrials.gov/study/NCT03660059	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Crohn's disease	FILGOTINIB	targetBased	3	Terminated	17/03/2017	https://clinicaltrials.gov/study/NCT02914600	0.7	LoF	protect	development program for filgotinib for participants with Crohn's disease has been stopped
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Crohn's disease	FILGOTINIB	targetBased	3	Completed	31/10/2016	https://clinicaltrials.gov/study/NCT02914561	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	immune system disease	FILGOTINIB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA45	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	FILGOTINIB	targetBased	3	Completed	14/11/2016	https://clinicaltrials.gov/study/NCT02914522	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	FILGOTINIB	targetBased	3	Active, not recruiting	23/02/2017	https://clinicaltrials.gov/study/NCT02914535	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	FILGOTINIB	targetBased	3	Terminated	26/07/2022	https://clinicaltrials.gov/study/NCT05479058	0.35	LoF	protect	the planned number of patients needed to ensure adequate precision in the estimations and to draw meaningful conclusions was unlikely to be met, questioning the scientific value and ethical grounds for study continuation
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	FILGOTINIB	targetBased	3	Completed	08/08/2016	https://clinicaltrials.gov/study/NCT02886728	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	FILGOTINIB	targetBased	3	Recruiting	03/03/2021	https://clinicaltrials.gov/study/NCT05090410	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	FILGOTINIB	targetBased	3	Completed	27/07/2016	https://clinicaltrials.gov/study/NCT02873936	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	FILGOTINIB	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	FILGOTINIB	targetBased	4	Not yet recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05502731	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	FILGOTINIB	targetBased	3	Completed	30/08/2016	https://clinicaltrials.gov/study/NCT02889796	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	FILGOTINIB	targetBased	4	Recruiting	12/05/2021	https://clinicaltrials.gov/study/NCT04985435	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	FILGOTINIB	targetBased	3	Active, not recruiting	28/02/2017	https://clinicaltrials.gov/study/NCT03025308	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208078s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Terminated	11/06/2018	https://clinicaltrials.gov/study/NCT03579966	0.7	LoF	protect	Lack of measure appropriate data (MG-ADL).
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Myasthenia gravis	AMIFAMPRIDINE PHOSPHATE	targetBased	3	Completed	18/04/2018	https://clinicaltrials.gov/study/NCT03304054	0.7	LoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	ETRASIMOD	targetBased	3	Completed	25/12/2020	https://clinicaltrials.gov/study/NCT04706793	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	ETRASIMOD	targetBased	3	Completed	15/09/2020	https://clinicaltrials.gov/study/NCT03996369	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	ETRASIMOD	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216956s000lbl.pdf	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	ETRASIMOD	targetBased	3	Completed	13/06/2019	https://clinicaltrials.gov/study/NCT03945188	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	ETRASIMOD	targetBased	3	Active, not recruiting	05/09/2019	https://clinicaltrials.gov/study/NCT03950232	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	ETRASIMOD	targetBased	3	Active, not recruiting	10/09/2019	https://clinicaltrials.gov/study/NCT04176588	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD	targetBased	3	Active, not recruiting	10/09/2019	https://clinicaltrials.gov/study/NCT04176588	0.7		protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD	targetBased	3	Active, not recruiting	10/09/2019	https://clinicaltrials.gov/study/NCT04176588	0.7		protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD	targetBased	3	Completed	13/06/2019	https://clinicaltrials.gov/study/NCT03945188	0.7		protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD	targetBased	3	Completed	13/06/2019	https://clinicaltrials.gov/study/NCT03945188	0.7		protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD	targetBased	3	Active, not recruiting	05/09/2019	https://clinicaltrials.gov/study/NCT03950232	0.7		protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD	targetBased	3	Active, not recruiting	05/09/2019	https://clinicaltrials.gov/study/NCT03950232	0.7		protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216956s000lbl.pdf	1		protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216956s000lbl.pdf	1		protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD	targetBased	3	Completed	25/12/2020	https://clinicaltrials.gov/study/NCT04706793	0.7		protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD	targetBased	3	Completed	25/12/2020	https://clinicaltrials.gov/study/NCT04706793	0.7		protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD	targetBased	3	Completed	15/09/2020	https://clinicaltrials.gov/study/NCT03996369	0.7		protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD	targetBased	3	Completed	15/09/2020	https://clinicaltrials.gov/study/NCT03996369	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	Crohn's disease	ETRASIMOD	targetBased	3	Recruiting	06/01/2020	https://clinicaltrials.gov/study/NCT04173273	0.7	GoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	Crohn's disease	ETRASIMOD	targetBased	3	Recruiting	06/01/2020	https://clinicaltrials.gov/study/NCT04173273	0.7		protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	Crohn's disease	ETRASIMOD	targetBased	3	Recruiting	06/01/2020	https://clinicaltrials.gov/study/NCT04173273	0.7		protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Crohn's disease	UPADACITINIB	targetBased	3	Not yet recruiting	22/07/2024	https://clinicaltrials.gov/study/NCT06227910	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Crohn's disease	UPADACITINIB	targetBased	3	Completed	07/12/2017	https://clinicaltrials.gov/study/NCT03345849	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Crohn's disease	UPADACITINIB	targetBased	3	Completed	29/11/2017	https://clinicaltrials.gov/study/NCT03345836	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Crohn's disease	UPADACITINIB	targetBased	3	Active, not recruiting	21/03/2018	https://clinicaltrials.gov/study/NCT03345823	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Crohn's disease	UPADACITINIB	targetBased	3	Not yet recruiting	26/07/2024	https://clinicaltrials.gov/study/NCT06332534	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	immune system disease	UPADACITINIB	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=L04AA44	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	UPADACITINIB	targetBased	4	Recruiting	30/09/2023	https://clinicaltrials.gov/study/NCT05867329	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	UPADACITINIB	targetBased	3	Active, not recruiting	31/01/2017	https://clinicaltrials.gov/study/NCT03006068	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	UPADACITINIB	targetBased	3	Completed	06/12/2018	https://clinicaltrials.gov/study/NCT03653026	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ulcerative colitis	UPADACITINIB	targetBased	3	Recruiting	06/11/2023	https://clinicaltrials.gov/study/NCT05782907	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	UPADACITINIB	targetBased	3	Completed	15/01/2020	https://clinicaltrials.gov/study/NCT04195698	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	UPADACITINIB	targetBased	3	Completed	21/02/2019	https://clinicaltrials.gov/study/NCT03738397	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	UPADACITINIB	targetBased	4	Active, not recruiting	12/05/2023	https://clinicaltrials.gov/study/NCT05507580	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	UPADACITINIB	targetBased	3	Completed	27/10/2018	https://clinicaltrials.gov/study/NCT03661138	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	UPADACITINIB	targetBased	3	Withdrawn	24/12/2020	https://clinicaltrials.gov/study/NCT04666675	0.7	LoF	protect	Strategic considerations
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	UPADACITINIB	targetBased	3	Enrolling by invitation	09/08/2018	https://clinicaltrials.gov/study/NCT03568318	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	UPADACITINIB	targetBased	3	Not yet recruiting	26/07/2024	https://clinicaltrials.gov/study/NCT06461897	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	UPADACITINIB	targetBased	3	Active, not recruiting	28/11/2022	https://clinicaltrials.gov/study/NCT05601882	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	UPADACITINIB	targetBased	3	Active, not recruiting	13/08/2018	https://clinicaltrials.gov/study/NCT03569293	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	atopic eczema	UPADACITINIB	targetBased	3	Active, not recruiting	27/07/2018	https://clinicaltrials.gov/study/NCT03607422	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	UPADACITINIB	targetBased	3	Completed	17/12/2015	https://clinicaltrials.gov/study/NCT02675426	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	UPADACITINIB	targetBased	3	Active, not recruiting	01/12/2015	https://clinicaltrials.gov/study/NCT02629159	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	UPADACITINIB	targetBased	3	Completed	23/02/2016	https://clinicaltrials.gov/study/NCT02706873	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	UPADACITINIB	targetBased	3	Completed	03/01/2018	https://clinicaltrials.gov/study/NCT02955212	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	UPADACITINIB	targetBased	3	Recruiting	12/01/2021	https://clinicaltrials.gov/study/NCT05121298	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	UPADACITINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	UPADACITINIB	targetBased	3	Completed	09/05/2017	https://clinicaltrials.gov/study/NCT03086343	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	UPADACITINIB	targetBased	4	Not yet recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05153200	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	UPADACITINIB	targetBased	3	Completed	23/03/2016	https://clinicaltrials.gov/study/NCT02706951	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	UPADACITINIB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	UPADACITINIB	targetBased	3	Completed	15/03/2016	https://clinicaltrials.gov/study/NCT02706847	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Vitiligo	UPADACITINIB	targetBased	3	Enrolling by invitation	19/12/2023	https://clinicaltrials.gov/study/NCT06118411	0.7	LoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	OZANIMOD HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	OZANIMOD HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	OZANIMOD HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93ce2fab-edfb-4804-8074-963071de51e4	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	OZANIMOD HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	immune system disease	OZANIMOD	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA38	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	OZANIMOD	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	OZANIMOD	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT06188637	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	OZANIMOD	targetBased	3	Recruiting	09/12/2022	https://clinicaltrials.gov/study/NCT05644665	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	OZANIMOD	targetBased	3	Active, not recruiting	03/06/2019	https://clinicaltrials.gov/study/NCT03915769	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	OZANIMOD	targetBased	3	Active, not recruiting	02/12/2015	https://clinicaltrials.gov/study/NCT02531126	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	OZANIMOD	targetBased	4	Recruiting	16/12/2022	https://clinicaltrials.gov/study/NCT05369832	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	OZANIMOD	targetBased	3	Completed	17/06/2015	https://clinicaltrials.gov/study/NCT02435992	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	Crohn's disease	OZANIMOD	targetBased	3	Completed	07/03/2018	https://clinicaltrials.gov/study/NCT03440385	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	Crohn's disease	OZANIMOD	targetBased	3	Recruiting	24/08/2018	https://clinicaltrials.gov/study/NCT03467958	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	Crohn's disease	OZANIMOD	targetBased	3	Active, not recruiting	27/02/2018	https://clinicaltrials.gov/study/NCT03440372	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	Crohn's disease	OZANIMOD	targetBased	3	Recruiting	27/06/2018	https://clinicaltrials.gov/study/NCT03464097	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	OZANIMOD	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	OZANIMOD	targetBased	3	Not yet recruiting	09/07/2024	https://clinicaltrials.gov/study/NCT06408259	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	OZANIMOD	targetBased	3	Completed	03/12/2013	https://clinicaltrials.gov/study/NCT02047734	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	OZANIMOD	targetBased	3	Active, not recruiting	16/01/2020	https://clinicaltrials.gov/study/NCT04140305	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	OZANIMOD	targetBased	4	Recruiting	31/01/2023	https://clinicaltrials.gov/study/NCT05777902	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	OZANIMOD	targetBased	3	Completed	03/12/2014	https://clinicaltrials.gov/study/NCT02294058	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	OZANIMOD	targetBased	3	Completed	16/10/2015	https://clinicaltrials.gov/study/NCT02576717	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	OZANIMOD	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93ce2fab-edfb-4804-8074-963071de51e4	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	OZANIMOD	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06334094	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	OZANIMOD	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	atopic eczema	PAC-14028	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02965118	0.7	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	PEFCALCITOL	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01873677	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	PEFCALCITOL	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01989429	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	PEFCALCITOL	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01908595	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	psoriasis	PEFCALCITOL	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01878461	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	ulcerative colitis	ETRASIMOD ARGININE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216956s000lbl.pdf	1		protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD ARGININE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216956s000lbl.pdf	1		protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	ulcerative colitis	ETRASIMOD ARGININE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216956s000lbl.pdf	1		protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIROXIMEL FUMARATE	targetBased	3	Recruiting	23/07/2021	https://clinicaltrials.gov/study/NCT04788615	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIROXIMEL FUMARATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIROXIMEL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d74414f-6b83-4ea2-9a95-3cecabbce774	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIROXIMEL FUMARATE	targetBased	3	Completed	10/12/2015	https://clinicaltrials.gov/study/NCT02634307	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	multiple sclerosis	DIROXIMEL FUMARATE	targetBased	3	Recruiting	18/11/2021	https://clinicaltrials.gov/study/NCT05083923	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIROXIMEL FUMARATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/vumerity	1	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	relapsing-remitting multiple sclerosis	DIROXIMEL FUMARATE	targetBased	3	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03093324	0.7	LoF	protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	immune system disease	DIROXIMEL FUMARATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AX09	1	LoF	protect
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	IFNG	Interferon gamma	macrophage activation syndrome	EMAPALUMAB	targetBased	3	Recruiting	15/12/2021	https://clinicaltrials.gov/study/NCT05001737	0.7	LoF	protect
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	IFNG	Interferon gamma	immune system disease	EMAPALUMAB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=L04AA39	1	LoF	protect
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	IFNG	Interferon gamma	Primary hemophagocytic lymphohistiocytosis	EMAPALUMAB	targetBased	3	Completed	06/02/2019	https://clinicaltrials.gov/study/NCT03312751	0.7	LoF	protect
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	IFNG	Interferon gamma	Primary hemophagocytic lymphohistiocytosis	EMAPALUMAB	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761107lbl.pdf	1	LoF	protect
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	IFNG	Interferon gamma	Primary hemophagocytic lymphohistiocytosis	EMAPALUMAB	targetBased	4	Active, not recruiting	03/02/2023	https://clinicaltrials.gov/study/NCT05744063	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	ulcerative colitis	COBITOLIMOD	targetBased	3	Terminated	24/11/2021	https://clinicaltrials.gov/study/NCT04985968	0.35	GoF	protect	Due to futility
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	ulcerative colitis	COBITOLIMOD	targetBased	3	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01493960	0.7	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	chronic progressive multiple sclerosis	SIPONIMOD FUMARATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	SIPONIMOD FUMARATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/mayzent	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	relapsing-remitting multiple sclerosis	SIPONIMOD FUMARATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	SIPONIMOD FUMARATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf	1	GoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	multiple sclerosis	SIPONIMOD FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44492772-5aed-4627-bd85-e8e89f308bb3	1	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis	FILGOTINIB MALEATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca	1	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	graft versus host disease	BELUMOSUDIL MESYLATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214783s000lbl.pdf	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis		targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	rheumatoid arthritis		targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf	1	LoF	protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

drTarget portfolio target-disease associations for immune system

DrTarget’s AI-Powered Insights into Immune System Disorders

Our AI-powered approach enables:

✔ Identification of key targets for autoimmune and inflammatory diseases✔ Drug repurposing opportunities for immune-modulating therapies✔ Pathway and biomarker analysis for precision immunology

By integrating AI-driven virtual screening with multi-source validation, DrTarget accelerates the discovery of next-generation immunotherapies to enhance treatment options for immune disorders.

Check best scored target-disease associations in table:

Some of these associations have also gone through clinical trials, as those in the graph below.

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.

✔ Identification of key targets for autoimmune and inflammatory diseases
✔ Drug repurposing opportunities for immune-modulating therapies
✔ Pathway and biomarker analysis for precision immunology